Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 29th, 2026

LECO_Weekly-Healthcare-News_6-29-2026Download
  1. The Doctors Company, the nation’s largest physician-owned medical malpractice insurer and parent of TDC Group, has completed its $1.3 billion all-cash acquisition of specialty insurer ProAssurance Corporation (NYSE: PRA) at $25.00 per share, creating a combined platform protecting more than 200,000 healthcare professionals nationwide. Napa, California-based The Doctors Company finalized its $1.3 billion buyout of ProAssurance (NYSE: PRA), acquiring all outstanding shares at $25.00 per share in cash — a transaction that ProAssurance shareholders had approved in June 2025. With the deal closed, PRA’s common stock has been delisted from the NYSE and deregistered with the SEC. The combined entity, operating under TDC Group, now holds $12 billion in assets and more than $2.5 billion in direct written premium, pairing The Doctors Company’s medical malpractice franchise with ProAssurance’s specialty lines spanning medical liability, medical technology and life sciences products liability, and workers’ compensation. ProAssurance will operate as a wholly owned subsidiary while an optimal structural review is conducted. (Link)
  2. Merck KGaA Agrees to Acquire Bio-Techne Corporation (NASD: TECH) for $11.3 Billion in Cash at $73 Per Share — a 36% Premium to the One-Month VWAP — in Merck KGaA’s Largest Acquisition Since the $17 Billion Sigma-Aldrich Deal in 2014 Merck KGaA, Darmstadt, Germany, entered into a definitive agreement on June 25, 2026 to acquire Minneapolis-based Bio-Techne (Nasdaq: TECH), a global provider of life science tools including 6,000 recombinant proteins, 425,000 antibodies, ProteinSimple analytical instruments, and RNAscope spatial biology technologies, for $73 per share in cash — a total enterprise value of approximately $11.3 billion. The transaction will be funded through existing cash and new debt while preserving an investment-grade rating, with Merck KGaA expecting immediate EBITDA accretion and approximately €140 million in annual cost synergies by year three; the deal is expected to close in late 2026 or early 2027 pending Bio-Techne shareholder and regulatory approvals. (Link)
  3. PsychPlus, a Houston-based psychiatric and therapeutic care provider, has acquired multinational digital mental health platform Koa Health to form what the companies describe as the world’s largest technology-enabled mental health company. PsychPlus completed its acquisition of Koa Health in an all-strategic transaction whose value was not disclosed, positioning the combined platform to serve more than 6 million patients across the US, Europe, Australia, and Asia-Pacific. The deal pairs PsychPlus’s proprietary clinical technology network — scaled to over 200 US locations in five years — with Koa Health’s digital-first delivery model, 56 patents, and 23 peer-reviewed studies. Led by CEO Dr. Faisal Tai, PsychPlus is investing to build an integrated, multi-channel care continuum; Koa Health founder Dr. Oliver Harrison joins as President. The combination targets faster patient access and a scalable global mental-health blueprint. (Link)
  4. Strata Critical Medical, Inc. (Nasdaq: SRTA) has acquired the Heart and Lung Transplant National Recovery Program (HLT-NRP) for $21.5 million to expand its national organ recovery platform. Strata Critical Medical (Nasdaq: SRTA) completed its purchase of HLT-NRP at a mid-single-digit multiple of pre-synergy Adjusted EBITDA, structured as roughly 80% cash and 20% stock subject to a multi-year lockup tied to the seller’s continued involvement. HLT-NRP is expected to generate approximately $10.0 million in revenue and $3.1 million in Adjusted EBITDA for full-year 2026. Co-CEOs Will Heyburn and Melissa Tomkiel framed the deal as adding clinical depth and geographic reach in Florida and California, deepening its fastest-growing Transplant Clinical line. CFO Mat Schneider emphasized the acquisition fits Strata’s capital allocation framework, expecting growth and operational synergies to lower the effective purchase price over time. (Link)
  5. AMR Clinical Acquires ClinOhio Research Services, Adding a Columbus, Ohio Multi-Therapeutic Clinical Research Site Specializing in Women’s Health, Dermatology, and Family Practice to Its 30+ Site National Network Knoxville, Tennessee-based AMR Clinical, a Curewell Capital-backed integrated research site organization with more than 30 U.S. locations and over 8,000 completed trials across more than 145,000 enrolled participants, announced on June 29, 2026 the acquisition of ClinOhio Research Services, a Columbus, Ohio-based multi-therapeutic clinical research facility specializing in Women’s Health, Dermatology, and Family Practice. The addition expands AMR’s geographic footprint into the Columbus market — home to The Ohio State University Wexner Medical Center and one of the most active clinical research ecosystems in the Midwest — and deepens its therapeutic capabilities across its Phase I–IV trial platform. AMR has grown to 30+ sites through a combination of acquisitions and organic site launches under Curewell Capital’s ownership. (Link)
  6. CareRite Centers has acquired the Grand Rehabilitation and Nursing at Queens from a Grand Healthcare System–linked entity (Clearview Land LLC) for $58.2 million. New Jersey–based CareRite Centers, an elder care and rehabilitation provider, deployed $58.2 million to acquire a 179-bed facility plus an adjacent parking lot in Whitestone, Queens, in a transaction recorded June 24. The deal closed April 28 and was signed for the buyer by co-founder and principal Mark Friedman. The seller, Clearview Land LLC, appears tied to Grand Healthcare System CEO Jeremy Strauss, whose New York network spans roughly 12 skilled nursing and rehab centers. The purchase price sits far above the property’s 2022 city-assessed market value of $8.1 million, marking a substantial premium as CareRite expands its regional footprint beyond its existing Brooklyn and Manhattan facilities. (Link)
  7. TELEO Capital Management has acquired pharmaceutical manufacturing intelligence platform SmartFactory Rx — now rebranded Modersys — from semiconductor-equipment maker Applied Materials, Inc. (NASDAQ: AMAT) in a corporate carve-out. Boise-based private equity firm TELEO Capital Management acquired Modersys (formerly SmartFactory Rx) from Applied Materials, Inc. (NASDAQ: AMAT) for an undisclosed sum, executing the carve-out strategy central to its lower-middle-market playbook. TELEO, which targets technology, software, and healthcare IT, will operate Modersys as an independent company to accelerate AI-driven product innovation for biopharma and life-sciences manufacturers. (Link)
  8. Incline Equity Partners has partnered with West Physics to expand its medical and health physics testing platform. Pittsburgh-based private equity firm Incline Equity Partners, which targets the middle market with enterprise values of $25–$750 million, backed Atlanta-headquartered West Physics, a market leader in accreditation and testing services for MRI, CT and X-ray imaging equipment. Financial terms were not disclosed. Managing Director Nic Meiring signaled the investment thesis: pursuing expansion into adjacent service offerings and new geographies both organically and through strategic M&A within a highly fragmented industry. Founder and CEO Dr. Geoff West will continue leading the company, planning to accelerate organic growth by investing in the services support structure, in-house residency program and broader physicist network. (Link)
  9. Chicago Pacific Founders has made a strategic growth investment in Attune, the Chicago-based Agentic Engagement Platform for Healthcare, to scale AI-driven patient coordination across value-based care. Healthcare-focused private equity firm and operator Chicago Pacific Founders (CPF) made an undisclosed strategic growth investment in Attune, an AI-powered patient-engagement platform. CPF — which manages more than 3 million lives across its value-based care network and invests exclusively in value-based care, healthcare services, and tech-enabled businesses — is deploying capital as an operator to embed Attune across its delivery models. The investment, framed by Co-Founder and Managing Partner Vance Vanier and Attune CEO Matt Coughlin, targets an estimated $430–480 billion in annual US care-coordination waste. Attune has outperformed human advocate teams, exceeding one Medicaid health-risk-assessment target by 40% within three weeks of going live. (Link)
  10. Hunterdon Health and Hackensack Meridian Health have signed a letter of intent to pursue a proposed merger of the two New Jersey nonprofit health systems. Flemington-based Hunterdon Health and Edison-based Hackensack Meridian Health signed a nonbinding letter of intent June 22 after both boards of trustees voted to advance merger exploration. The letter of intent is nonbinding and does not represent a final deal, with no immediate changes to patient care, staffing or compensation. As a nonprofit combination, no purchase price applies; the strategic rationale centers on pooling resources, technology and expertise to expand services, invest in clinical research, and compete against larger, better-resourced systems. Leaders Patrick Gavin and Robert Garrett cited mission alignment and patient-centered innovation as both parties work toward a definitive agreement. (Link)
  11. DermDox Group has acquired Modern Aesthetics Plastic Surgery, expanding its dermatology, aesthetics and specialty healthcare platform. DermDox Group, a growing platform focused on dermatology, aesthetics and specialty healthcare services, completed a strategic transaction acquiring Modern Aesthetics Plastic Surgery. The deal reflects sustained strategic-buyer and investor demand for high-quality assets in the aesthetics and elective healthcare sectors, where consolidation continues across physician practices, med spas, plastic surgery and dermatology. The acquisition expands DermDox’s capabilities within the aesthetic and surgical services market while providing Modern Aesthetics with additional resources to support future growth and patient care initiatives. (Link)
  12. New York-based investment group Black Pearl Equities has entered into a definitive agreement to acquire all outstanding shares of Selectis Health, Inc. (OTCQB: GBCS), a Denver-based skilled nursing and senior living operator, for $5.75 per share in cash in a transaction valued at an implied premium to market.Brooklyn, New York-based Black Pearl Equities has agreed to acquire Selectis Health (OTCQB: GBCS) through a cash tender offer at $5.75 per share — a deal unanimously approved by Selectis’s Board of Directors as fair and in the best interests of stockholders. The transaction, structured as a tender offer followed by a short-form merger under the Utah Revised Business Corporation Act, requires valid tender of at least 70% of outstanding shares and carries no financing contingency. The deal is expected to close in Q3 2026. Selectis currently operates eight skilled nursing, assisted living, and independent living properties across Arkansas and Oklahoma, serving Medicare, Medicaid, and private-pay residents. Black Pearl, a healthcare-focused investment and advisory firm, will take Selectis private as a wholly owned subsidiary. (Link)
  13. Standard Dental Labs Inc. has signed a letter of intent to acquire an additional dental laboratory in the Tampa Bay region. Orlando-based dental laboratory consolidator Standard Dental Labs (OTCQB: TUTH) executed a non-binding LOI to acquire an established, undisclosed dental lab in Tampa Bay, advancing its strategy of building a regional Florida network. President and CEO James D. Brooks said the firm continues identifying high-quality labs whose owners value joining a larger organization. The LOI follows the company’s acquisition of BRLIT Dental Laboratory last month and remains subject to due diligence and definitive agreements. Brooks emphasized that developing regional density creates economies of scale and long-term shareholder value, with an active acquisition pipeline across Central Florida driven by owner succession planning and consolidation pressures. (Link)
  14. Fortitude Mining Holdings, Inc., currently wholly owned by Digital Currency Group (DCG), has agreed to combine with HeartSciences Inc. (Nasdaq: HSCS) in an all-stock business combination to take its vertically integrated Zcash mining platform public. Digital Currency Group, the sole stockholder of Fortitude Mining Holdings, will hold approximately 95% of the combined company on a fully diluted basis at closing, reflecting continued conviction in the venture mining business. Fortitude and HeartSciences (Nasdaq: HSCS) entered a definitive all-stock merger agreement expected to close in the second half of 2026, with the combined entity operating under the Fortitude brand and trading on Nasdaq under the ticker “TUDE,” subject to approval. DCG founder and CEO Barry Silbert framed Zcash as one of the most compelling opportunities in digital assets, pairing Bitcoin-style scarcity and Proof-of-Work discipline with privacy properties. The public listing gives Fortitude capital-markets access to scale its mining platform. (Link)

Venture Deals and Other

  1. GRAIL, Inc. (Nasdaq: GRAL) has completed a $110 million equity financing from Samsung entities, including Samsung C&T Corporation, to fund its growth and international expansion. GRAIL (Nasdaq: GRAL) closed a $110 million equity investment from Samsung affiliates. The Samsung entities purchased GRAIL common stock at $70.05 per share, representing a long-term investment supporting GRAIL’s growth and international expansion. The strategic capital strengthens GRAIL’s balance sheet and extends its cash runway as it pursues U.S. regulatory approval and reimbursement for its Galleri multi-cancer early detection test. GRAIL and Samsung C&T intend to collaborate to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore. Samsung C&T, which has invested in Samsung Biologics, continues building its biopharmaceutical and life sciences portfolio through this milestone deal. (Link)
  2. Assort Health has raised a $120 million Series C led by Menlo Ventures, with backing from Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures and Quiet Capital, reaching unicorn status. Assort Health secured $120 million in Series C funding, hitting unicorn status, to scale its voice AI agent platform for healthcare. Menlo Ventures led the round, joined by Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures and Quiet Capital. Menlo partner Matt Murphy cited Assort’s category leadership, strong ROI and proven specialty-care execution. The company has raised $222 million to date and hit a $1.2 billion valuation, with revenue jumping 20x in 15 months. Investors are betting on Assort’s proprietary specialty dataset and Synapse AI model as defensible moats in a rapidly consolidating, capital-intensive market. (Link)
  3. xCures has raised a $46 million Series B led by Innovius Capital, with participation from iGrow, GKCC and Spring Mountain Capital, to scale its clinical data structuring platform. xCures completed a $46 million Series B financing led by Innovius Capital, with heavy participation from iGrow, GKCC, Spring Mountain Capital and existing institutional investors. The round pushes the company’s total institutional funding past $76 million to scale its Clinical Clarity Engine, which turns unstructured medical records into decision-ready data. Innovius Capital partner Stu Posluns emphasized that the future of healthcare AI depends on the accuracy, completeness and trust profile of underlying clinical data. xCures has processed more than 300 million medical records from over 550,000 healthcare locations, a defensive moat investors view as difficult for lightweight entrants to replicate. (Link)
  4. Prosper AI has raised a $30 million Series A led by Andreessen Horowitz (a16z), with participation from Base10, Emergence Capital, Y Combinator and Company Ventures, to build an AI workforce for healthcare operations. Prosper AI banked $30 million to scale its agentic AI platform powering administrative tasks from patient scheduling to insurance verification and patient billing. Andreessen Horowitz led the Series A round, with participation from Base10 and continued support from Emergence Capital, Y Combinator and Company Ventures. a16z partner Jay Rughani cited the founders’ ambition and strong competitive win rates as the conviction drivers, noting the platform’s end-to-end pull-through across customers. The funding follows roughly 5x revenue growth since the September seed round; capital will expand engineering and customer teams and deepen integrations across major EHR platforms. (Link)
  5. Rapalogix Health Raises $20 Million in Series A Financing to Advance Its Pipeline of Longevity-Based Skin Health Products Targeting the mTOR Pathway, a Scientifically Validated Mechanism Linked to Cellular Aging and Skin Regeneration Carlsbad, California-based Rapalogix Health, a biotechnology company pioneering longevity-based skin health through mTOR pathway modulation, closed a $20 million Series A to advance its proprietary product pipeline and expand commercial operations. Rapalogix is developing prescription and consumer products using rapamycin analogs targeting mTOR — a cellular pathway linked to aging, inflammation, and skin regeneration — in a category positioned at the intersection of dermatology, longevity medicine, and aesthetic health as investor and consumer interest in science-backed longevity products accelerates. (Link)
  6. Hera has raised a $27 million Series A led by Bain Capital Ventures, with participation from Accel and IA Ventures, to expand its AI-powered senior care coordination platform. Hera raised $27 million in Series A funding led by Bain Capital Ventures, with continued participation from Accel and IA Ventures. Angel investors also participated, including the CFO of Mount Sinai. Bain Capital Ventures partner Alysaa Co praised the founding team’s mix of personal conviction and technical depth honed at Headway and Palantir, viewing Hera’s platform as one that learns what genuinely helps aging families rather than merely surfacing options. The capital will fund continued buildout of Hera’s AI platform and expansion into California, Florida, Maryland, Pennsylvania and Massachusetts, targeting more than 25 states by year-end after reaching 95% retention across over 1,000 families. (Link)
  7. Pathway Labs has raised an $8.5 million seed round led by AlleyCorp and Breyer Capital to deploy its FDA-cleared cardiology AI tool, alongside a partnership with OpenEvidence. Pathway Labs announced an $8.5 million seed round led by AlleyCorp and Breyer Capital to expand deployment across health systems, grow its clinical and commercial teams, and support ongoing R&D. The financing coincides with the launch of EchoNext, the first FDA-approved AI tool reading standard ECGs to flag structural heart disease. Breyer Capital’s Dr. Morgan Cheatham praised the company for surfacing imperceptible diagnostic signals from widely ordered tests, while AlleyCorp’s Dr. Alexi Nazem called the technology a pioneering new type of AI-enabled medicine. The capital will fund integration into real clinical workflows at national scale via the OpenEvidence platform. (Link)
  8. Upside has secured a $20 million Series A led by Aquiline, with participation from Flare Capital Partners and existing investors 645 Ventures, Freestyle Capital, Triple Impact Capital and Techstars. Upside banked a $20 million Series A to address the U.S. housing crisis through a healthcare lens. Aquiline led the round, with participation from Flare Capital Partners and support from existing investors 645 Ventures, Freestyle Capital, Triple Impact Capital and Techstars. Aquiline partner Dante La Ruffa framed housing instability as a persistent driver of avoidable healthcare spend and pointed to strategic connectivity across health plan, payer and broker channels. The funding will be deployed simultaneously across Medicaid, Medicare Advantage and employer-sponsored markets, funding leadership hires, operational depth and continued technology investment as Upside scales its housing stability platform. (Link)
  9. Anodyne Nanotech Closes $12.6 Million Series A Led by Velocity Partners VC to Advance ANN-101 — a Once-Weekly GLP-1 Transdermal Patch for Obesity Requiring No Injection or Cold Storage — into Phase I Clinical Trials Boston-based Anodyne Nanotech closed a $12.6 million Series A co-led by Velocity Partners VC and Evercurious VC, with major participation from Relativity Healthcare Partners, to advance ANN-101, its once-weekly GLP-1 patch for obesity, into Phase I clinical trials and scale manufacturing of its HeroPatch™ transdermal delivery platform capable of delivering multi-milligram weekly GLP-1 doses without an injection or cold storage. The financing also supports Anodyne’s pipeline including an apelin/GLP-1 combination patch designed to counter lean-muscle loss — a key side effect of current GLP-1 injectable therapies. (Link)
  10. Ladder Health has raised a $7 million seed round led by Nina Capital, with participation from Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, White Oak Enterprises, Groove Capital and 7Rock Ventures. Ladder Health raised $7 million in an oversubscribed seed round led by Nina Capital to expand its virtual-first pediatric developmental care platform. Additional investors included Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, White Oak Enterprises, Groove Capital and 7Rock Ventures. The diversified syndicate is backing a company addressing nationwide provider shortages and waitlists for pediatric therapy. The capital will support expansion across North Carolina, Massachusetts and Maryland, entry into additional markets, enhancement of its AI-enabled care platform, and deeper partnerships with pediatric practices and health systems. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 22nd, 2026

LECO_Weekly-Healthcare-News_6-22-2026Download
  1. Apollo Global-Backed Thoreau Group Signs Definitive Agreement for Strategic Growth Investment in Ensemble Health Partners, the Nation’s Largest RCM Managed Services Provider, at an Approximately $12 Billion Valuation Thoreau Group — the healthcare investment platform founded by former New Mountain Capital executive Matt Holt and backed by Apollo Global Management — signed a definitive agreement on June 17–18, 2026 to make a strategic growth investment in Ensemble Health Partners at an estimated $12 billion valuation. Ensemble manages more than $55 billion in net patient revenue annually across 200+ hospitals and approximately 12,000 employees, serving major health systems through billing, payment, and AI-enabled RCM services — including an RCM-native large language model developed in partnership with Cohere — following a $4.75 billion dividend recapitalization completed in January 2026. Legacy investors Berkshire Partners, Warburg Pincus, and Bon Secours Mercy Health will continue as co-investors. The transaction positions Thoreau at the center of the scaled healthcare administrative outsourcing sector. (Link)
  2. Abry Partners has closed a $780 million single-asset continuation fund anchored by Neuberger Berman and Apollo S3 (NYSE: APO) to retain its investment in Centauri Health Solutions, while simultaneously divesting Centauri’s Provider Solutions business to Elevate, a portfolio company of Audax Private Equity and Parthenon Capital Partners. Boston-based private equity firm Abry Partners orchestrated a $780 million single-asset continuation fund to extend its ownership of Centauri Health Solutions — a healthcare technology company serving U.S. health plans and health systems — transferring the asset from Abry Fund IX into the new vehicle. The Continuation Fund was co-anchored by Neuberger Berman and Apollo S3 (NYSE: APO), with additional commitments from Abry’s existing LP base. Concurrently, Centauri’s Provider Solutions business was divested to Elevate, a portfolio company of Audax Private Equity and Parthenon Capital Partners, sharpening Centauri’s focus as a pure-play payer technology and data intelligence platform. Since Abry’s 2020 investment, Centauri’s payer business tripled revenue and quadrupled EBITDA. (Link)
  3. Altaris has agreed to acquire Simulations Plus (Nasdaq: SLP) for approximately $375 million in an all-cash transaction, representing a 26% premium to the company’s 60-day volume-weighted average price, with the deal expected to close in Q4 2026. New York-based Altaris, an investment firm managing over $9 billion in equity capital with an exclusive focus on healthcare, has entered into a definitive agreement to acquire Simulations Plus (Nasdaq: SLP) at $18.50 per share in cash. Altaris anticipates combining the target with Chemical Computing Group (CCG), an existing Altaris portfolio company focused on molecular design software, to create a more integrated AI-driven drug development platform. The all-cash transaction, unanimously approved by Simulations Plus’s board, is financed through committed equity and debt from Altaris-affiliated funds without a financing contingency. Simulations Plus co-founder Dr. Walter Woltosz has entered into a voting support agreement backing the deal. The transaction is expected to close in Q4 2026 subject to stockholder and regulatory approvals. (Link)
  4. Abarca Health and LucyRx Announce Strategic Combination to Create the Only Modern PBM Built for Commercial and Government Scale Abarca Health and LucyRx have announced a strategic combination to form a modern, independent pharmacy benefit manager (PBM) with the scale and technology to serve commercial and government clients nationwide. The combined entity, operating under the parent brand Healthcare Revolution Partners, will provide prescription services to more than 9 million members. Abarca contributes its Darwin Healthcare Intelligence platform — a cloud-native, configurable PBM technology stack — while LucyRx brings clinical capabilities and deep expertise serving employers and labor groups. Both brands will continue operating as subsidiaries with no disruption to clients or members. The combination arrives amid ongoing scrutiny of traditional PBM consolidation and demand for transparent, independent alternatives. (Link)
  5. Singlepoint Healthcare Acquires Healix, Expanding National Infusion Capabilities Singlepoint Healthcare has acquired Healix, a leading provider of outpatient infusion management services operating more than 220 physician-owned and ambulatory infusion centers nationwide. The deal enhances Singlepoint’s integrated care model for inflammatory diseases by adding specialized infusion services spanning infectious disease, gastroenterology, neurology, rheumatology, and related therapeutic areas. This marks Singlepoint’s third acquisition in the past year, reflecting an accelerated buy-and-build strategy in the outpatient infusion market — a high-growth segment driven by biosimilar adoption, site-of-care migration from hospitals to lower-cost settings, and increasing prevalence of chronic inflammatory conditions. Healix will continue its focus on optimizing patient care in outpatient settings following integration. (Link)
  6. Aldrich Capital Partners-backed Compliancy Group has acquired Healthicity, a leading provider of healthcare compliance and auditing software, to create the most comprehensive combined platform for healthcare compliance programs serving more than 3,000 healthcare organizations. Compliancy Group, the healthcare compliance SaaS platform backed by growth equity investor Aldrich Capital Partners, has acquired Healthicity, a provider of healthcare auditing and compliance software including Compliance Manager and Audit Manager+ solutions. The combination creates the first unified platform delivering end-to-end coverage of provider, coding, and documentation auditing alongside workforce compliance, risk assessment, and incident management for a combined customer base exceeding 3,000 U.S. healthcare organizations (Link)
  7. ChartSpan Acquires Validic, the Leading Personal Health Data Platform, Creating a Unified Clinical Care Management and Remote Patient Monitoring Platform for Health Systems, Payers, and Life Sciences Companies Greenville, SC-based ChartSpan, a leading care management services company, announced on June 22, 2026 the completed acquisition of Validic, the healthcare industry’s leading personal health data platform connecting wearable and clinical devices to health system workflows. The combined company unites ChartSpan’s clinical care teams and Chronic Care Management, Advanced Primary Care Management, and Remote Patient Monitoring services with Validic’s global IoT and health data API infrastructure, device logistics, and RPM software — enabling organizations to move from periodic observation to continuous patient understanding. (Link)
  8. Ohio-based Align Capital Partners’ portfolio company Premier Biotech (based in Cleveland, Ohio and Dallas, Texas) has acquired both NexScreen and TransMed, representing the firm’s seventh acquisition since partnering with ACP in November 2022. Cleveland, Ohio-based Align Capital Partners (ACP), a growth-oriented private equity firm managing $3.2 billion in committed capital, has executed two simultaneous bolt-on acquisitions through its drug and alcohol testing portfolio company Premier Biotech: NexScreen, a point-of-care diagnostic testing solutions provider operating across the U.S., Australia, and New Zealand; and TransMed, a broad-catalog drug testing and lab supply distributor with over 1,000 direct customer accounts and a global e-commerce platform. These transactions mark Premier Biotech’s sixth and seventh acquisitions under ACP’s ownership since November 2022, extending the company’s international footprint and product offering across healthcare, government, and workplace markets. (Link)
  9. Cleargate Capital Partners has made a strategic investment in Fellow Health Partners, a Bay Shore, New York-based provider of revenue cycle management services to more than 500 clinicians across approximately 50 healthcare organizations nationwide. Healthcare-focused private equity firm Cleargate Capital Partners, founded in 2025, has made an undisclosed strategic investment in Fellow Health Partners, a leading RCM services provider to physician groups, ambulatory surgery centers, and specialty healthcare organizations across the U.S. Cleargate’s investment is intended to fund growth across Fellow’s SAVi technology platform,capital to pursue add-on acquisitions. Fellow’s existing management team, led by CEO Michael N. Brown, will continue to lead the organization. The deal supports Cleargate’s thesis of backing founder-led, lower-middle-market healthcare businesses with partnerships. (Link)
  10. AI-Native Medicare Navigation Platform Connie Health Completes Acquisition of Clearlink’s Medicare Business — Its 10th Acquisition — Alongside a $40 Million Series B Led by HealthQuest Capital, Bringing Total Funding to $85 Million Boston-based Connie Health, the AI-native Medicare navigation platform, has completed its acquisition of Clearlink Insurance Agency’s Medicare business — its 10th acquisition — while closing a $40 million Series B led by HealthQuest Capital with participation from JSL Capital, Khosla Ventures, aMoon, and Pitango HealthTech. The round brings total funding to $85 million. The integration leverages Connie’s AI and automation platform to seamlessly absorb the large-scale book while maintaining personalized service through its network of local trusted agents. Capital will support continued national expansion, technology investment, and additional acquisitions as Connie deepens its role as a strategic partner for value-based care organizations and ACOs. (Link)
  11. Tredence Acquires KMK Consulting, a Morris Plains, NJ-Based Life Sciences Analytics Firm Serving 8 of the World’s Top 10 Pharmaceutical Companies, to Build a Scaled Healthcare and Life Sciences AI Platform Tredence, a global AI and data science solutions firm, has acquired KMK Consulting, a specialized analytics and consulting firm with deep expertise in pharmaceuticals and life sciences headquartered in Morris Plains, New Jersey. KMK partners with 8 of the world’s top 10 pharmaceutical companies and brings over two decades of domain expertise in commercial analytics, real-world evidence (RWE), and market research. The deal positions Tredence to expand its Healthcare & Life Sciences business by combining KMK’s domain depth with Tredence’s Agentic AI capabilities across the full molecule-to-market development journey. (Link)
  12. Interlock Equity-Backed VeloSource Simultaneously Acquires Quest Locum Tenens and Syncx LLC, Adding National Physician Staffing Scale and a Proprietary Vendor-Neutral Workforce Management Technology Platform St. Louis-based VeloSource LLC, a portfolio company of Interlock Equity, has acquired Quest Locum Tenens and Syncx LLC to build an enterprise healthcare workforce ecosystem. The deals expand VeloSource’s national clinical staffing capabilities and add Syncx’s proprietary vendor-neutral technology platform for workforce management, including a differentiated physician float pool model that digitizes scheduling and prioritizes internal resources before external placement. Quest brings additional nationwide placement expertise for physicians, nurse practitioners, physician assistants, and CRNAs. The combined platform aims to address clinician shortages and improve operational efficiency for healthcare organizations. (Link)
  13. Avista Healthcare Partners-backed EBI has acquired Xstim, a division of Precision Medical Products Inc., to expand its bone growth stimulation portfolio and reinforce its position as the only pure-play bone growth stimulation company. EBI, a portfolio company of New York-based Avista Healthcare Partners — which has invested over $10 billion across more than 50 healthcare businesses globally — has acquired Xstim, the bone healing division of Precision Medical Products Inc. Xstim’s next-generation, wearable, capacitively coupled electrical stimulation therapy for lumbar spinal fusion is highly complementary to EBI’s existing FDA-approved portfolio of implantable and non-invasive bone healing solutions, including the EBI® Bone Healing System, OrthoPak®, and SpinalPak®. The deal advances Avista’s strategy of building differentiated, growth-oriented healthcare product platforms with clear scale potential and broadens EBI’s total addressable market across spinal fusion, nonunion fracture, and joint fusion applications. (Link)
  14. HR HealthCare Acquires SteriGear LLC and Fig Leaf Brand, Expanding Urology Solutions Across the Care Continuum York, PA-based HR HealthCare has acquired SteriGear LLC, including the Fig Leaf brand of urinary drainage devices and related covers and drapes, to strengthen its bladder management portfolio across acute, post-acute, and home care settings. The Fig Leaf product emphasizes patient dignity with privacy features, while SteriGear’s solutions complement HR HealthCare’s TruCath line. The deal creates a more comprehensive urology platform accessible through a single source, consolidating procurement for hospital systems and post-acute care providers. The Fig Leaf brand will continue operating under its existing name, with the SteriGear brand transitioning into HR HealthCare’s portfolio over time. (Link)
  15. Michigan Ear Institute Partners with Align ENT & Allergy, Expanding Access to Specialized Ear, Hearing, and Balance Care Across Michigan and Ohio Under a Physician-Led MSO Model Michigan Ear Institute (MEI), headquartered in Farmington Hills, Michigan, has entered into a strategic partnership with Align ENT & Allergy, a physician-led management services organization. The transaction closed on March 25, 2026, and expands access to specialized ear, hearing, and balance care across Michigan and Ohio. MEI operates four locations and is recognized for advanced diagnostic and treatment options. The partnership aligns MEI with Align’s MSO model focused on operational support, billing, and practice management while preserving full clinical autonomy for its physicians. (Link)
  16. Brightstar Capital Partners Acquires Erdman, a Madison, WI-Based Architecture and Engineering Firm Specializing in Healthcare Facilities and Senior Living Communities, to Expand Its Architecture and Design Platform Brightstar Capital Partners has acquired Erdman, a Madison, Wisconsin-based architecture and engineering firm founded in 1951 specializing in healthcare facilities and senior living communities. Licensed in more than 45 states, Erdman joins KZF Design in Brightstar’s architecture and design platform and contributes its proprietary ZeroIn healthcare analytics platform — a data-driven tool for optimizing facility design and operational performance. The deal supports growing demand for healthcare and senior living construction driven by an aging population and expands Brightstar’s national footprint in healthcare facility design and development. (Link)
  17. PruittHealth Acquires Four Home Health Offices in South Georgia, Adding 36 Counties to Expand Its Statewide Service Area to 109 Counties Under the PruittHealth @ Home Brand PruittHealth has acquired four home health offices in South Georgia — Community Health Services of Georgia locations in Vidalia and Albany, and Georgia Home Health Services locations in Valdosta and Tifton — adding 36 counties to its service area for a total of 109 counties statewide. The acquired offices will operate under the PruittHealth @ Home brand and integrate into PruittHealth’s existing home health network. This expansion reinforces PruittHealth’s position as a leading provider of home health services across Georgia, continuing the organization’s strategy of geographic densification within its core market through targeted acquisitions of established home health agencies. (Link)
  18. Jennie Stuart Health Acquires Six Medical Practices Across Western Kentucky, Including Generations Primary Care, MDVIP, Hopkinsville Family Care, and Three Additional Clinics, Strengthening Regional Provider Coordination Jennie Stuart Health has acquired six medical practices — Generations Primary Care, MDVIP, Hopkinsville Family Care, Western Kentucky Pulmonary Clinic, Elkton Clinic, and Crofton Clinic — to expand access to primary and specialty care across western Kentucky. Patients will continue receiving care from the same providers at their current locations with no interruption in services, and MDVIP will maintain its existing direct primary care membership model. The acquisition strengthens provider coordination, improves specialist access, and supports the long-term stability of regional healthcare delivery in underserved rural and semi-rural Kentucky communities. (Link)
  19. Legend Senior Living Acquires Apple Blossom Senior Living in Moon Township, Pennsylvania, Expanding to 78 Residences Across Eight States as Part of Its Ongoing Pennsylvania Growth Strategy Legend Senior Living has acquired Apple Blossom Senior Living in Moon Township, Pennsylvania, as part of its ongoing Pennsylvania expansion. The community offers Independent Living cottages along with Personal Care and Memory Care options. With this addition, Legend now operates 78 senior living residences across eight states. The acquisition strengthens Legend’s presence in the greater Pittsburgh market and continues its family-led approach focused on personalized resident support, dignity, and quality of life. Legend’s acquisition strategy targets established communities in growing suburban markets where demand for senior living services is supported by favorable demographic trends. (Link)
  20. Imagen Dental Partners Adds Pineview Aesthetic & Family Dentistry in Bellevue, Washington, Expanding Its Pacific Northwest Presence with a Practice Founded in 2007 by Repeated Seattle Top Dentist Honoree Dr. Gannon Stahl Imagen Dental Partners has partnered with Pineview Aesthetic & Family Dentistry, a leading Bellevue, Washington practice founded in 2007 and led by Dr. Gannon Stahl, a University of Washington School of Dentistry graduate and repeated Seattle Top Dentist honoree. The practice offers comprehensive family, cosmetic, restorative, and implant dentistry using advanced clinical technology and a patient-first approach. Dr. Stahl will continue focusing on clinical excellence while gaining access to Imagen’s support infrastructure across recruiting, marketing, revenue cycle management, and operations — a structure consistent with the supported independence model common across dental service organization partnerships. (Link)
  21. New Jersey Medical Office Building and ASC Portfolio — Including Physician’s SurgiCenter — Sells for $13.6 Million; Two-Building Medical Portfolio in Toms River 99% Leased at Close A medical office building portfolio in Toms River, New Jersey, including Physician’s SurgiCenter, has sold for $13.6 million. The two-building Holiday City Medical Portfolio totals 55,680 square feet and was 99% leased at closing, with established tenants including Labcorp, University Radiology Group, Asetera Cancer Care, Premier Dermatology, Elite Podiatry, and several others. Horizon Equities sold the properties to an undisclosed buyer following strong investor interest, with nearly a dozen competing offers received. The transaction reflects continued investor appetite for stabilized, multi-tenant medical office and ambulatory surgery center assets in established suburban New Jersey healthcare markets. (Link)
  22. Group Benefit Services Acquires Integrity Administrators, a Sacramento, CA-Based Third-Party Administrator, Expanding Its Self-Funded Health Plan Administration Platform with Enhanced Nurse Navigator and Member Services Capabilities Group Benefit Services, Inc. (GBS) has acquired Integrity Administrators, Inc. (IAI), a third-party administrator based in Sacramento, California specializing in self-funded health plan administration. The combination enhances GBS’s platform with expanded resources, Nurse Navigator programs, and a high-touch service model focused on cost savings and member support. IAI clients will benefit from GBS’s broader infrastructure and national network while maintaining the personalized service approach that defines the IAI model. The transaction continues consolidation in the fragmented TPA market, where self-funded employers increasingly seek scaled administrators with clinical care coordination capabilities alongside traditional plan administration services. (Link)

Venture Deals and Other

  1. Samsung Electronics (KRX: 005930) has made a $175 million investment in Element Biosciences’ upsized Series E financing round, becoming the genomic and multiomic technology company’s largest shareholder, with an undisclosed amount from other co-investors also participating. Samsung Electronics (KRX: 005930) has committed $175 million into an upsized Series E financing round for Element Biosciences, a San Diego-based life sciences company specializing in DNA sequencing and multiomic technologies. Samsung, a longstanding investor in Element, will become its largest shareholder upon close, pending regulatory approvals. The investment reflects Samsung’s strategic confidence in Element’s growing product ecosystem — including AVITI, VITARI, and the forthcoming AVITI Dx and AVITI24 — and aligns with its broader precision medicine and life sciences innovation mandate. Proceeds will fund global commercialization, geographic expansion, and advancement of the company’s product roadmap across research, translational science, and diagnostic applications. (Link)
  2. Avataar Ventures has led a $28.5 million Series B round in Bengaluru-based deep-tech manufacturing startup Ethereal Machines, with participation from existing investor Peak XV Partners, to fund a new manufacturing facility, indigenous CNC technology development, and global market expansion. Bengaluru-based deep-tech firm Ethereal Machines has raised $28.5 million in a Series B round led by Avataar Ventures, with Peak XV Partners participating as a returning investor. The capital, arriving nearly two years after the company’s $13 million Series A, is earmarked to construct a new 300,000-square-foot automated manufacturing plant under an MOU with the Karnataka government, develop a proprietary multi-axis CNC controller, and expand into the U.S. and European markets. Ethereal Machines’ MaaS business has grown threefold year-on-year since its Series A and production capacity has expanded tenfold. The company targets sectors including aerospace, defense, semiconductor manufacturing, and consumer electronics. (Link)
  3. Echo Health Ventures and FMZ Ventures have co-led a $30 million Series C in InStride Health, with existing investors Valtruis, .406 Ventures, General Catalyst, and Mass General Brigham Ventures also participating, bringing the pediatric mental health company’s total raised to $86 million. InStride Health, a provider of insurance-based virtual specialty treatment for children, teens, and young adults with anxiety and OCD, has closed a $30 million Series C co-led by Echo Health Ventures — the strategic CVC arm of the Blue Cross Blue Shield collaborative network — and FMZ Ventures, a growth equity firm specializing in digitally enabled consumer marketplace companies. Existing investors Valtruis, .406 Ventures, General Catalyst, and Mass General Brigham Ventures also participated. The round brings InStride’s total capital raised to $86 million and will fund geographic expansion from 17 states to Midwest and Western markets and deepening of payer relationships with insurers including Aetna, Anthem, Cigna, and UnitedHealthcare. (Link)
  4. Index Ventures has led a $7 million seed round in Uncovr, with Seedcamp, Frst, No Labels Ventures, and Entrepreneurs First also participating, to fund the AI surgical documentation startup’s expansion across U.S. and European hospital systems. Uncovr, a surgical AI company that analyzes intraoperative video to automatically generate procedural coding and operative reports, has secured $7 million in seed funding led by Index Ventures, with Seedcamp, Frst, No Labels Ventures, and Entrepreneurs First among additional investors. Digital Surgery founder Jean Nehme, Color Health CEO Othman Laraki, and Meta board member Charlie Songhurst also contributed individually to the round. Uncovr, launched in 2025 and currently deployed across more than 400 operating rooms in the U.S. and Europe, has identified a 16% missed-billable-step rate and a ~10% reimbursement gap in procedures. The seed capital will be deployed to hire ML engineers and expand hospital partnerships. (Link)
  5. Bonfire Ventures, Supernode, Comma Capital, and individual investor Jacquelyn Kung have backed Vali Health with $6 million in funding as the San Francisco-based AI home care startup emerges from stealth. Vali Health, a San Francisco-based startup building AI infrastructure for the home care industry, has emerged from stealth with $6 million in funding from Bonfire Ventures, Supernode, Comma Capital, and individual investor Jacquelyn Kung. Founded by Serena Dang (CEO) and Jason Wu (CTO), Vali Health has built an AI-native 24/7 safety infrastructure designed to help mid-sized home care agencies automate workforce management and coordination, saving upwards of 20 hours per week. The startup has achieved 400% growth in just 12 months, now serving agencies across nearly 100 locations in 30 states. Capital will be used to expand operations and market reach. (Link)
  6. Vanna Health Raises $17 Million to Expand Evidence-Based Care for People Living with Serious Mental Illness Vanna Health, a value-based health technology company providing integrated mental and chronic health support through community-based coaching, has raised $17 million in funding co-led by a national healthcare insurer and AlleyCorp, with participation from Health Velocity Capital. The capital will support expansion of its clinical reach, technology infrastructure, and recovery-oriented care model for individuals with serious mental illness (SMI) such as schizophrenia and bipolar disorder. Vanna Health currently operates in four states and aims to scale its community-centered, technology-enabled approach nationwide. (Link)
  7. Khosla Ventures has led an $11 million seed round in Clair Health, with participation from a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki, to develop the first continuous, non-invasive wearable hormone monitor for women. Clair Health, a femtech startup co-founded by Stanford graduates Jenny Duan and Abhinav Agarwal, has raised $11 million in seed funding led by Khosla Ventures, with a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and 23andMe co-founder Anne Wojcicki also contributing. The startup is building a wearable wristband leveraging a proprietary stack of 10 biosensors — including biomagnetic sensors not found in any competing consumer wearable — combined with AI models to continuously infer a woman’s hormonal cycle phase without blood draws or skin piercing. With a 25,000-person waitlist and a sold-out presale, Clair Health plans a November 2026 wellness product launch and subsequent pursuit of FDA clearance for applications across fertility, perimenopause, and hormone conditions. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 15th, 2026

LECO_Weekly-Healthcare-News_6-15-2026Download

Healthcare Weekly News and Deals –June 15th, 2026

  1. Danaher Corporation (NYSE: DHR) has completed its acquisition of Masimo Corporation (NASD: MASI), a leading patient monitoring company, for a total enterprise value of approximately $9.9 billion in cash Danaher (NYSE: DHR) completed its acquisition of Masimo (NASDAQ: MASI) on June 10, 2026, paying $180 per share in cash — a deal valued at roughly $9.9 billion including assumed debt and net of acquired cash. The transaction, which represents approximately 18x estimated 2027 EBITDA, adds Masimo’s industry-leading pulse oximetry and specialty diagnostics portfolio to Danaher’s Diagnostics segment. Danaher expects the acquisition to generate more than $530 million in Masimo EBITDA in 2027 and has targeted over $125 million in annual cost synergies and $50 million in annual revenue synergies by the fifth post-close year, funded through cash on hand and debt proceeds. (Link)
  2. GSK plc (NYSE: GSK) has entered into a definitive agreement to acquire Nuvalent, Inc. (NASD: NUVL), a precision oncology biotech with two late-stage non-small cell lung cancer candidates currently under FDA review, for $10.6 billion in cash. GSK plc announced on June 9, 2026 a definitive agreement to acquire Cambridge, Massachusetts-based Nuvalent (NASDAQ: NUVL) for $124 per share in cash — a 40% premium to last close and aggregate equity consideration of $10.6 billion, or approximately $9.4 billion net of acquired cash. The acquisition centers on two late-stage assets under active FDA review: zidesamtinib (ROS1-positive NSCLC) and neladalkib (ALK-positive NSCLC), both of which could launch by year-end 2026 and are projected to generate combined revenues exceeding $800 million by 2029. (Link)
  3. Chiesi Group has completed its approximately $1.9 billion acquisition of KalVista Pharmaceuticals, Inc. (NASD: KALV), adding EKTERLY® (sebetralstat) — the first and only oral, on-demand treatment for hereditary angioedema — to its Rare Diseases business unit. Chiesi Group, the Parma, Italy-based research-focused biopharmaceutical group, completed its acquisition of KalVista Pharmaceuticals (NASDAQ: KALV) on June 11, 2026, paying $27.00 per share in cash following a tender offer in which approximately 77.8% of shares were validly tendered, for aggregate consideration of approximately $1.9 billion. With the closing, Chiesi assumes ownership of EKTERLY® (sebetralstat), a plasma kallikrein inhibitor approved in the U.S., EU, UK, and Japan for the treatment of acute hereditary angioedema (HAE) attacks in patients aged 12 and older. (Link)
  4. Novanta Inc. (NASD: NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a category leader in minimally invasive surgical consumables, from Arlington Capital Partners for $1.2 billion in upfront cash plus a $250 million milestone payment Novanta (NASDAQ: NOVT) struck a deal to acquire Riverpoint Medical from Arlington Capital Partners, a Washington D.C.-area private investment firm, for $1.2 billion upfront and up to $250 million in milestone payments due in Q1 2027 — implying a total potential consideration of $1.45 billion. The acquisition is priced at approximately 19x Riverpoint’s estimated 2026 Adjusted EBITDA and is expected to immediately accrete to Novanta’s 2026 adjusted EPS. Strategically, the deal doubles Novanta’s recurring medical consumables revenue to roughly $300 million and lifts medical end-market exposure to approximately 60% of total revenue, with Novanta financing the deal via cash on hand, a $300 million equity raise, and existing credit facilities. (Link)
  5. Humana Inc. (NYSE: HUM) has signed a definitive agreement to divest all or substantially all of its approximately 40% minority interest in Gentiva, the nation’s largest hospice and palliative care provider, to a consortium of investors for approximately $900 million. Humana (NYSE: HUM) announced on June 10, 2026 a definitive agreement to sell substantially all of its minority interest in Gentiva — the nation’s leading hospice and end-of-life services provider operating more than 430 locations across 35 states — to an undisclosed consortium of investors for approximately $900 million. Proceeds will be directed to general corporate purposes. Closing is expected in Q3 2026, subject to regulatory approvals and customary conditions. (Link)
  6. Medtronic plc (NYSE: MDT) has completed its acquisition of Scientia Vascular, a privately-held neurovascular access device maker, for $550 million with potential additional earn-out and milestone payments Medtronic (NYSE: MDT) completed its acquisition of Salt Lake City-based Scientia Vascular in June 2026 for $550 million — a deal originally signed in March 2026. Scientia’s portfolio of advanced guidewires and catheters is designed to improve physician navigation through complex cerebral vasculature, and will integrate seamlessly into Medtronic’s existing neurovascular product line to support full procedural workflows for stroke and neurovascular interventions. With approximately 310 employees, Scientia represents Medtronic’s latest strategic neurovascular investment, following similar sector consolidation plays by Boston Scientific and Stryker. (Link)
  7. Keenova Therapeutics plc has agreed to sell its Percocet and Endocet opioid prescription drug businesses to Par Health, Inc. for total consideration of approximately $250 million, fully exiting the opioid market upon close. Keenova Therapeutics plc announced on June 13, 2026 a purchase agreement with Par Health, Inc. to divest its Percocet (oxycodone HCl/acetaminophen) and Endocet branded prescription opioid businesses for total consideration of approximately $250 million — comprising a $25 million upfront payment, subject to customary adjustments, plus quarterly earnout payments based on the gross profit of the divested business over a five-year period post-close. The transaction is expected to close in Q3 2026, subject to HSR antitrust clearance and customary closing conditions. Following the completion of all related obligations, Keenova will no longer market, manufacture, or distribute opioid products, representing a full strategic exit from the category. The divestiture allows Keenova to refocus capital allocation on its core non-opioid pipeline priorities. (Link)
  8. Adial Pharmaceuticals, Inc. (NASD: ADIL) has acquired Azora Therapeutics, Inc. and its lead colon-targeted ulcerative colitis candidate AT177, concurrent with a private placement of up to $64 million led by Coastlands Capital. Adial Pharmaceuticals (NASDAQ: ADIL) announced on June 11, 2026 the acquisition of Azora Therapeutics in a stock exchange transaction, adding Azora’s lead asset AT177 — a proprietary oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist in IND-enabling studies for ulcerative colitis — as the combined company’s primary pipeline focus. Concurrent with the acquisition, Adial entered into a private placement of up to $64 million: $32 million upfront, led by Coastlands Capital, with a potential additional $32 million tranche tied to clinical milestones. Following shareholder approval and securities conversion, former Azora shareholders are expected to own approximately 51% of the combined company, financing investors approximately 41.3%, and existing Adial shareholders approximately 7.7%. Adial shares rose approximately 35% on announcement. (Link)
  9. Sagility (NSE: SAGILITY) has acquired CareSeed, a Kansas City-based healthcare analytics company specializing in HEDIS quality reporting and Medicare Advantage performance, for up to approximately $30 million. Sagility, a tech-enabled healthcare operations company backed by institutional investors, acquired CareSeed in a deal valued at up to $30 million — comprising $17.5 million upfront and up to $12.5 million in earn-outs tied to performance. Founded in 2012 and based in Kansas City, Missouri, CareSeed serves 30 small and mid-sized U.S. payers through its cloud-native Forecast and Harvest platforms, generating $5.1 million in CY25 revenue at a 31.4% EBITDA margin. The acquisition is expected to be immediately EPS accretive to Sagility and adds 28 new Medicare Advantage health plan relationships, positioning Sagility to deliver an end-to-end quality operations continuum from HEDIS abstraction to prospective care gap closure. (Link)
  10. SK Capital Partners-backed Spectrum Vascular has acquired Piccolo Medical, developer of 510(k)-cleared proprietary blood-flow sensing catheter guidance technology, to deepen its vascular access platform and accelerate commercialization of the Nav+ Stylet. Spectrum Vascular, a White Plains, New York-based vascular access and medication management products company backed by SK Capital Partners, announced on June 11, 2026 the acquisition of Piccolo Medical, a developer of next-generation catheter guidance products more than a decade in development. Piccolo’s real-time catheter guidance uses proprietary blood-flow sensing technology to precisely guide catheter tip placement, eliminating the need for confirmatory chest X-rays — a standard and costly step in most vascular access procedures. Piccolo completed its first successful patient placements of the Nav+ Stylet in May 2026. Augustus Shanahan, CEO of Piccolo, will join Spectrum alongside his team to advance development and commercialization. (Link)
  11. Vizient has acquired Empierus, a healthcare-focused IT contracting and cost optimization advisory firm, to expand its indirect spend management capabilities across a sector spending more than $55 billion annually on information technology. Vizient, the Irving, Texas-based provider-driven healthcare performance improvement company with a $156 billion annual purchasing portfolio, announced on June 11, 2026 the acquisition of Empierus, a healthcare advisory firm specializing in IT contracting, healthcare technology management, and cost optimization. Through an existing partnership, Empierus delivered more than $36 million in savings for Vizient clients in 2025 alone; Empierus employees will join Vizient’s team of more than 250 indirect spend and purchased services experts. The acquisition addresses a rapidly growing, largely unmanaged category as healthcare organizations expand IT investments in cybersecurity, cloud, AI, and digital transformation. (Link)
  12. Capsa Healthcare, backed by Francisco Partners, has acquired The Harloff Company, a leading manufacturer of healthcare storage and mobility products, for undisclosed terms to deepen its clinical workflow solutions portfolio Canal Winchester, Ohio-based Capsa Healthcare — acquired by private equity firm Francisco Partners in April 2026 for approximately $500 million — has made its first add-on acquisition by purchasing The Harloff Company, a 75-year-old manufacturer of medical storage cabinets, procedure carts, medication storage systems, and endoscopic processing solutions. The combination integrates Harloff’s durable clinical infrastructure with Capsa’s tech-enabled pharmacy automation and point-of-care platforms, creating a more comprehensive healthcare equipment offering for hospitals, ambulatory surgery centers, and long-term care facilities. (Link)
  13. Grant Avenue Capital-backed PatientCare EMS Solutions has partnered with Superior Mobile Health, a Texas-based provider of non-emergency medical transportation services, expanding its geographic footprint into the Texas market PatientCare EMS Solutions, a New York-headquartered ground-based healthcare transportation platform backed by private equity firm Grant Avenue Capital, announced a strategic partnership with Superior Mobile Health, a San Antonio, Texas-based provider founded in 2011. Superior completed more than 80,000 patient transports in 2025 across a network of over 300 clinical staff, with strong existing relationships with Texas hospitals, municipalities, and nursing facilities. The partnership gives Superior access to PatientCare’s capital resources, operational infrastructure, fleet technology, and scale — and marks PatientCare’s entry into the Texas market under its buy-and-build strategy with Grant Avenue as sponsor. Terms were not disclosed. (Link)
  14. Alembic Therapeutics, LLC has acquired NUVESSA® (metronidazole vaginal gel 1.3%), an FDA-approved single-dose prescription treatment for bacterial vaginosis, from Exeltis USA, Inc. to expand its women’s health portfolio. Bedminster, New Jersey-based Alembic Therapeutics announced on June 9, 2026 the acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc., assuming full U.S. commercialization and distribution responsibilities. NUVESSA is an FDA-approved, single-dose, pre-filled disposable applicator indicated for the treatment of bacterial vaginosis in females aged 12 and older — the most common vaginal infection in women of childbearing age, affecting an estimated 21 million U.S. women annually. (Link)
  15. Chambers Home Health & Hospice, a Northeast Texas home-based care provider founded in 2002, has partnered with Lucent Health Group. Chambers Home Health & Hospice, a Melissa Chambers-founded provider of skilled home health and hospice services across more than 20 counties in Northeast Texas operating through three agencies — Chambers Home Health, Chambers Hospice, and Healthcare Associates LLC — announced on June 10, 2026 a partnership with Lucent Health Group (LHG). The transaction positions Chambers to build on over two decades of regional growth while accessing LHG’s capital resources and healthcare operating expertise to support continued expansion across a growing home-based care market. Cross Keys Capital served as exclusive financial advisor to Chambers; Calhoun, Bhella & Sechrest provided legal counsel. (Link)
  16. Gemspring Capital ($5.1 billion AUM) has acquired Freedom Senior Services, a multi-state provider of culturally responsive home care, adult day, IDD, and VA services across Kentucky, Indiana, Ohio, Pennsylvania, and Tennessee Gemspring Capital Management, LP, a Westport, Connecticut-based middle market private equity firm with $5.1 billion of capital under management, acquired Freedom Senior Services, a provider of culturally responsive home care, adult day, intellectual and developmental disability (IDD), and VA services operating across Kentucky, Indiana, Ohio, Pennsylvania, and Tennessee. The transaction, announced in June 2026, was advised by Livingstone Partners on behalf of Gemspring. Freedom’s multilingual care delivery model and regional concentration in the Midwest and Appalachian markets positions it as a differentiated platform within a fragmented home- and community-based services sector facing strong demographic tailwinds. (Link)
  17. Apex Paramedics has been sold to Royal Ambulance, a California-based medical transportation provider, in a transaction advised by Helix Health Capital Advisors, marking Royal’s entry into the Colorado market. Helix Health Capital Advisors served as exclusive financial advisor to Apex Paramedics, a Denver-based provider of scheduled non-emergent interfacility transport (IFT) services, in its sale to Royal Ambulance announced June 9, 2026. Founded in 2015, Apex serves the Denver metro and Colorado Springs markets under multi-year service agreements with leading health systems. Royal Ambulance, a California-based provider of medical transportation and specialty transport services across the San Francisco Bay Area, expands its geographic footprint beyond Northern California through the acquisition and gains a scalable IFT platform in a high-growth Colorado market. (Link)
  18. 10x Genomics, Inc. (NASD: TXG) has acquired Proteintech Genomics, a division of Proteintech Group, to expand its proteomics and single-cell multiomic capabilities. 10x Genomics (NASDAQ: TXG) announced on June 9, 2026 the acquisition of Proteintech Genomics, a division within Proteintech Group, adding its Human Discovery Panel — the largest antibody-based single-cell protein panel currently available — designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles within sequencing-compatible workflows on 10x’s Chromium Flex chemistry. The acquisition is strategically timed to complement 10x’s April 2026 launch of the Atera whole-transcriptome single-cell platform, advancing the company’s multiomic vision by bridging proteomic and transcriptomic layers at single-cell resolution.  , and 10x Genomics stated the transaction will not meaningfully impact its near-term financial outlook. (Link)
  19. AMN Healthcare Services (NYSE: AMN) has acquired Jaide Health, a Boston-based AI-enabled medical interpretation and translation startup, for undisclosed terms to expand language access solutions across the patient journey AMN Healthcare Services (NYSE: AMN) acquired Jaide Health through its Language Services division in June 2026 to pair AI-assisted language tools with AMN’s existing human interpreter network. Jaide Health’s platform provides real-time, AI-enabled support for routine verbal exchanges and written translations — such as patient intake and discharge communications — addressing language access gaps for Limited English Proficiency (LEP) patients outside clinical encounters. The acquisition is consistent with AMN’s broader strategy of deploying technology solutions that reduce friction across the care continuum. (Link)
  20. PartsSource, a leading clinical technology performance platform, has acquired SkillNet, a healthcare workforce intelligence platform for hospital technology management teams, for undisclosed terms. Cleveland, Ohio-based PartsSource announced on June 9, 2026 the acquisition of SkillNet, a Workforce Intelligence platform purpose-built for healthcare technology management (HTM) departments. SkillNet provides hospitals and health systems with real-time visibility into technician competency compliance, skill-gap assessment, and team capability tracking — enabling HTM leaders to close critical technician deficiencies and expand care capacity. The acquisition extends PartsSource’s Enterprise Clinical Technology platform beyond parts procurement, service optimization, and asset performance management into the workforce intelligence layer, creating a more comprehensive operating system for hospital biomed and clinical engineering departments. (Link)
  21. Chinook Investment Partners has made a growth equity investment in PractiVet, a Scottsdale, Arizona-based veterinary infusion and syringe pump device company, with debt financing support from Mercantile Bank. Chinook Investment Partners, a Castle Pines, Colorado-based private equity firm focused on healthcare and business services, completed a growth investment in PractiVet in April 2026 through a transaction supported by Mercantile Bank. Founded in 2007 and headquartered in Scottsdale, Arizona, PractiVet is a leading branded supplier of infusion and syringe pump devices and IV infusion consumables serving thousands of veterinary hospitals and universities nationwide, with more than 30,000 devices deployed across specialty, emergency, and academic settings. The deal is consistent with Chinook’s strategy of backing profitable, growth-stage companies in recession-resilient healthcare end markets with revenues between $5 million and $100 million and EBITDA between $1 million and $10 million. (Link)

Venture Deals and Other

  1. Vida Ventures has led an oversubscribed $125 million Series B investment in SonoThera, with participation from ARK Invest, Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures SA, CureDuchenne Ventures, Vivo Capital, SymBiosis, and a roster of prominent existing investors to advance ultrasound-mediated nonviral genetic medicines. Vida Ventures led a highly syndicated $125 million Series B in South San Francisco-based SonoThera, joined by new investors ARK Invest (NYSE: ARKK), Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures, CureDuchenne Ventures, Vivo Capital, and SymBiosis, alongside returning backers including ARCH Venture Partners, Alexandria Venture Investments, Illumina Ventures, Johnson & Johnson Innovation – JJDC, RA Capital, Duquesne Family Office, Medical Excellence Capital, and Vertex Ventures HC. The oversubscribed round will advance SonoThera’s lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic, with the first DMD trial targeted for 2027. SonoThera’s proprietary RIPPLE™ ultrasound delivery and PORE™ payload engineering platforms represent a novel nonviral alternative to traditional gene therapy. (Link)
  2. Viking Global Investors has led an oversubscribed $100 million Series E financing in GT Medical Technologies, with participation from MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures, to accelerate commercialization of its GammaTile brain tumor radiotherapy platform. Viking Global Investors — a global investment firm managing over $52 billion in assets — led an oversubscribed $100 million Series E in Tempe, Arizona-based GT Medical Technologies, joined by re-upping investors MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The round follows compelling Phase 3 ROADS trial data presented at ASCO 2026 showing GammaTile — the company’s FDA-cleared bioresorbable radiation implant — reduced tumor recurrence risk by 93% and death risk by 41% at 12 months versus standard of care. Proceeds will fuel commercial and operational expansion and support the BRIDGES RCT in glioblastoma patients. This round follows a $53 million Series D completed in 2025. (Link)
  3. Atlas Venture and Medicxi Ventures have co-led a combined $101 million Series A and Series B financing in Ethyreal Bio, an ophthalmic biotech emerging from stealth to develop a first-in-class IGF-1R inhibitor for thyroid eye disease and Graves’ disease. Ethyreal Bio emerged from stealth on June 10, 2026 with $101 million in combined financing — a Series A co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital, followed by a Series B led by Avoro Capital with all Series A investors participating. The company’s lead asset, ETHY-001, is a first-in-human candidate targeting the insulin-like growth factor 1 receptor (IGF-1R) for thyroid eye disease (TED) and Graves’ disease, entering a market currently anchored by Amgen’s Tepezza (teprotumumab), which generated over $2 billion in peak annual sales. Proceeds will fund ETHY-001 into Phase 1, planned for later in 2026, with a differentiated mechanism targeting potential improvements in tolerability versus the current standard of care. (Link)
  4. Prime Radiant Partners has invested $50 million in Cellares, the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy, growing its Series D to $327 million and bringing total capital raised to $739 million. Cellares, the South San Francisco-based IDMO pioneering automated cell therapy manufacturing, announced on June 15, 2026 a $50 million investment from Prime Radiant Partners, growing its Series D financing — originally anchored by BlackRock and Eclipse — to $327 million total, with total capital raised reaching $739 million. The new capital supports Cellares’ global Smart Factory buildout spanning South San Francisco, Bridgewater (NJ), Leiden (Netherlands), and Kashiwa City (Japan), targeting commercial-scale production in 2027. Cellares has manufactured and delivered the first GMP doses of Cabaletta Bio’s investigational CAR-T therapy on its Cell Shuttle® platform, signed a 10-year supply agreement with Cabaletta, and secured a $380 M global manufacturing agreement with Bristol Myers Squibb for commercial-scale cell therapy capacity. (Link)
  5. Caffeinated Capital has led an oversubscribed $23 million Series A investment in Neion Bio, with participation from Basis Set Ventures and other new investors, to advance the company’s egg-based biologics manufacturing platform. Caffeinated Capital, an early-stage technology-focused fund and original seed backer of Neion Bio, led the New York-based biotech’s oversubscribed $23 million Series A, with new investors including Basis Set Ventures, Clocktower Ventures, and Hawktail also joining the round. Neion Bio deploys frontier genetic engineering to convert chicken eggs into highly efficient biological manufacturing vessels for complex, glycosylated proteins — positioning the company as an infrastructure-layer alternative to traditional cell culture-based biologic production. The financing follows Neion’s March 2026 emergence from stealth and its announcement of a commercial co-development and supply agreement with a major pharmaceutical company for a multi-product biosimilars collaboration. (Link)
  6. Tau Ventures, Upstream Ventures, Proofpoint Capital, Draper Associates, Wicklow Capital, and 29 additional investors have co-invested in a $24 million Series A round in Klinic Inc., a Texas-based specialty healthcare provider-enablement platform. Klinic Inc., a Frisco, Texas-based healthcare technology company, closed a $24 million equity financing round backed by 34 investors — including Tau Ventures, Upstream Ventures, Proofpoint Capital, Draper Associates, and Wicklow Capital. Founded in 2021 by Avish Bhama and Dan Cheung, Klinic operates as a Shopify-like infrastructure layer for independent specialty practices across 12 medical disciplines including oncology, cardiology, and rare diseases, providing unified tools for patient acquisition, EHR, RCM, prior authorization tracking, and care coordination. The company’s first round sale closed in January 2026 per an SEC Form D filing, and proceeds are expected to fund aggressive platform expansion across North American specialty markets. (Link)
  7. Shore Search Partners has led a Series A growth investment in Aton Health, a Kansas City-based healthcare company embedding research infrastructure into routine specialty care to generate real-world evidence at scale. Aton Health, based in Kansas City, Missouri, announced on June 12, 2026 the closing of a Series A growth investment led by Shore Search Partners, the healthcare-focused venture arm of Shore Capital Partners — which closed $850 million across two new funds in 2025. Aton integrates its TrialSight™ and CareSight™ data collection platforms directly into existing specialty practices, enabling providers to participate in non-interventional research programs — beginning in gastroenterology and expanding into additional specialties — without disrupting clinical workflows. The model connects pharmaceutical sponsors with high-quality, real-world patient populations at the point of care, addressing structural limitations of traditional clinical trial site access. Investment amount was not disclosed. (Link)
  8. Index Ventures has led a €6 million ($7 million) seed round in Uncovr, a Paris- and New York-based surgical AI startup, with participation from Seedcamp, Frst, No Label Ventures, Entrepreneurs First, and notable healthcare angels, to build AI infrastructure that converts surgical video into clinical records. Index Ventures — one of Europe’s most active technology venture funds — led the debut seed round in Uncovr, joined by institutional backers Seedcamp, Frst, No Label Ventures, and Entrepreneurs First, as well as angel investors including Digital Surgery founder Jean Nehme (whose prior company was acquired by Medtronic (NYSE: MDT)), Color Health CEO Othman Laraki, and Meta board member Charlie Songhurst. Uncovr’s AI platform analyzes real-time surgical and endoscopic video to automatically generate operative reports and procedural billing codes, addressing a structural documentation gap affecting more than 400 million surgeries annually. The company plans to use the capital to scale its AI platform and expand into U.S. hospital systems. (Link)
  9. NVENTRIC, a South Korean medical device company specializing in vascular intervention, has closed a ₩34.5 billion (~$22.6 million) pre-IPO financing round from 14 institutional investors, including Loftyrock Investment, Moneyball Ventures, Shinhan Capital, IPS Ventures, and LB Investment, to fund global expansion and a planned KOSDAQ listing. NVENTRIC attracted 14 new institutional backers to its pre-IPO round, with Shinhan Capital, IPS Ventures, Quad Asset Management, and Heungkuk Securities participating as follow-on investors from prior rounds alongside new commitments from Loftyrock Investment, Moneyball Ventures, Moneyball Partners, Scale-up Partners, AJU IB Investment, HB Investment, Pacific Capital, Flexus Partners, and Heungkuk Securities. The company has achieved a 52.9% CAGR in cumulative revenue over the past four years, posting approximately $3.9 million in total revenues through the period. Proceeds from the round will fund global commercial expansion and accelerate NVENTRIC’s preparations for a KOSDAQ IPO. (Link)
  10. Institutional healthcare investors and company insiders have participated in a $10.5 million private placement financing in CervoMed Inc. (NASD: CRVO), a clinical-stage biotech developing treatments for age-related neurological disorders. CervoMed (NASDAQ: CRVO) raised $10.5 million in a private placement led by institutional healthcare investors, with meaningful insider co-investment from board chairman Joshua S. Boger, Ph.D. — founder of Vertex Pharmaceuticals (NASDAQ: VRTX) — alongside trusts affiliated with CEO Dr. John Alam and board member Sylvie Grégoire. The company sold 3,360,377 units at $3.14 per unit, with Series B and C warrants that could generate an additional $21.7 million in gross proceeds if fully exercised. Proceeds will fund ongoing development of neflamapimod, an oral neuroinflammation inhibitor being advanced toward Phase 3 for dementia with Lewy bodies, while supporting pursuit of a strategic partnership, and are expected to extend CervoMed’s cash runway into Q2 2027. (Link)
  11. Arcadia Biosciences (NASD: RKDA) has raised $4 million through an at-the-market private placement of common stock and preferred investment options under Nasdaq rules to fund working capital and general corporate purposes. Arcadia Biosciences (NASDAQ: RKDA), a Dallas-based producer and marketer of wellness products including its Zola coconut water brand, completed a $4 million private placement priced at $1.03 per share on June 12, 2026, issuing 3,883,496 common shares with accompanying Series A-1 and A-2 preferred investment options exercisable at $0.91 per share. Investors attracted to RKDA’s at-the-market structure, which bypasses shareholder approval requirements under Nasdaq Rule 7.1 provisions, drove a notable 18%+ single-day stock price surge on the announcement. Proceeds will be directed toward working capital needs and general corporate operations as the company continues executing on its consumer wellness portfolio strategy. (Link)
  12. Institutional investors have participated in an $8.5 million private placement in Bluejay Diagnostics (NASD: BJDX), a Massachusetts-based near-patient testing company, with total potential proceeds of up to $23.7 million if warrants are fully exercised. Bluejay Diagnostics (NASDAQ: BJDX), headquartered in Acton, Massachusetts, closed an $8.5 million private placement on June 5, 2026, issuing 3,655,917 shares at $2.325 per share alongside two series of warrants — Series G (exercisable for five years) and Series H (short-term) — each covering up to 3,655,917 additional shares at a $2.075 exercise price. If warrants are fully exercised, total gross proceeds could reach approximately $23.7 million, which BJDX estimates would extend its cash runway well beyond its anticipated FDA approval and first full year of commercialization. Near-term proceeds are targeted toward clinical studies supporting regulatory clearance and R&D activities. (Link)
  13. New and existing institutional and sophisticated investors have collectively committed A$30 million to Vitrafy Life Sciences (ASX: VFY) through a non-underwritten institutional placement to fund manufacturing expansion and accelerate U.S. market entry for its Guardion cryopreservation devices. Vitrafy Life Sciences (ASX: VFY), an Australian life sciences company focused on smart cryopreservation solutions, secured firm commitments for a A$30 million (~US$19.5 million) institutional placement on June 10, 2026, issuing approximately 11.54 million new shares at A$2.60 per share — a 31.6% discount to its last closing price. The capital raise is directed toward three key uses: A$15 million for Guardion device fleet inventory build, A$8 million for U.S. sales and operational scaling, and A$5.2 million for working capital. The placement, backed by both new and existing institutional backers, supports Vitrafy’s positioning ahead of the 2027 blood industry replacement cycle in the U.S., where the company has partnered with Vitalant for frozen red blood cell preservation solutions. (Link)

Market Rumors

  1. Matt Holt’s Thoreau Group, backed by Apollo Global Management, is reported to be in advanced talks to acquire Ensemble Health Partners, a leading revenue cycle management company, in a deal valuing the business at approximately $12 billion. Bloomberg reported on June 12, 2026 that Thoreau Group — the healthcare technology platform created by former New Mountain Capital managing director and president Matt Holt, backed by Apollo Global Management — is in advanced talks to acquire Ensemble Health Partners and that a deal could be signed imminently. Cincinnati-based Ensemble Health Partners is one of the largest revenue cycle management companies in the U.S., generating approximately $2.7 billion in annual revenues serving major health systems. Thoreau Group is expected to become the controlling shareholder of Ensemble. The reported valuation of approximately $12 billion would represent one of the largest healthcare services transactions of 2026. No parties have confirmed the report. This item is based solely on Bloomberg reporting and should be treated as unconfirmed pending an official announcement. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 8th, 2026

LECO_Weekly-Healthcare-News_6-8-2026Download

Healthcare Weekly News and Deals –June 8th, 2026

  1. New Brunswick, NJ-based Johnson & Johnson (NYSE: JNJ) agreed to acquire Firefly Bio, Inc. for $1 billion in cash to add its Firelink™ degrader antibody conjugate (DAC) platform targeting KRAS-driven and other hard-to-treat solid tumors, expanding J&J’s next-generation oncology pipeline Johnson & Johnson (NYSE: JNJ) announced on June 8, 2026 a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company developing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ platform delivers a highly selective protein degrader to tumor cells while avoiding healthy cells, targeting KRAS-driven solid tumors — among the most prevalent and historically hard-to-treat oncology targets. The acquisition adds preclinical candidates and a novel modality complementing J&J’s existing antibody engineering expertise across monoclonal antibodies, bispecifics, and ADCs. Closing is expected later in 2026, subject to regulatory approvals and customary conditions. (Link)
  2. Wilmington, Delaware-based Incyte Corporation (NASD: INCY) agreed to acquire Vega Therapeutics — a wholly owned subsidiary of Star Therapeutics — for $1.25 billion upfront plus up to $750 million in sales milestones (up to $2.0 billion total), adding VGA039, a Phase 3-ready first-in-class monoclonal antibody for von Willebrand disease Incyte Corporation (NASD: INCY) announced on June 8, 2026 a definitive agreement to acquire Vega Therapeutics, Inc. from Star Therapeutics, LLC for $1.25 billion upfront plus up to $750 million in sales milestone payments, totaling up to $2.0 billion. Vega’s lead candidate, VGA039, is a first-in-class investigational monoclonal antibody modulating Protein S to improve hemostasis in von Willebrand disease (VWD) — the most common inherited bleeding disorder, affecting approximately 135,000 diagnosed U.S. patients. VGA039 is in Phase 3 pivotal development as a potentially first-ever subcutaneous prophylactic therapy for VWD patients who currently require frequent IV infusions; it holds FDA Breakthrough Therapy and Orphan Drug designations. Closing is expected in Q3 2026, subject to antitrust clearance. (Link)
  3. Nashville-based Ascension health system finalized its $3.9 billion acquisition of ASC operator AMSURG — adding 250 ambulatory surgery centers across 34 states — after the FTC required divestitures of seven surgery centers, creating one of the largest nonprofit health system-owned ambulatory surgery portfolios in the country Ascension, one of the largest nonprofit health systems in the United States, closed its $3.9 billion acquisition of AMSURG following an FTC consent order requiring divestiture of seven ASCs in five metropolitan markets to SCA Health — a subsidiary of UnitedHealth Group’s (NYSE: UNH) Optum — and one additional ASC. The acquisition adds 250 ASCs across 34 states to Ascension’s existing portfolio of 58 wholly owned surgical centers, dramatically expanding its outpatient surgery footprint. Industry observers view the deal as a catalyst for broader ASC sector consolidation. (Link)
  4. Joplin, Missouri-based Freeman Health System completed the $110 million acquisition of Northwest Health from Community Health Systems (NYSE: CYH), adding four Arkansas hospital facilities and marking Freeman’s first expansion into the state Freeman Health System finalized the $110 million purchase of Northwest Health from Community Health Systems (NYSE: CYH). The transaction included substantially all assets of four hospitals — Northwest Medical Center Bentonville, Northwest Medical Center Springdale, Willow Creek Women’s Hospital in Johnson, and Siloam Springs Regional Hospital — plus associated outpatient centers and practices, bringing approximately 2,200 employees into the Freeman organization. The deal marks Freeman Health’s inaugural geographic expansion into Arkansas, adding significant hospital density in the rapidly growing Northwest Arkansas market. (Link)
  5. Aveanna Healthcare Holdings (NASD: AVAH) has completed the acquisition of Family First Homecare for $175.5 million, adding 27 pediatric home care locations across seven states to its national platform. Atlanta-based Aveanna Healthcare Holdings (NASD: AVAH), a diversified home care platform serving medically complex patient populations, has closed its $175.5 million all-cash acquisition of Family First Homecare, a scaled multi-state provider of pediatric private duty nursing services. Funded entirely from cash on hand, the transaction adds 27 locations across Florida, Illinois, Iowa, North Carolina, Pennsylvania, South Dakota, and Texas to Aveanna’s portfolio. The deal lifts Aveanna’s full-year 2026 revenue guidance by $70 million to a range of $2.63–$2.65 billion, and increases its Adjusted EBITDA guidance by $10 million to a range of $338–$342 million, reflecting immediate financial accretion from the deal. (Link)
  6. Parsippany, NJ-based Med-Metrix (PE: Harvest Partners and A&M Capital Partners) entered into a definitive agreement to acquire Vitalware from Health Catalyst (NASD: HCAT) for $147 million in cash, strengthening its mid-revenue cycle technology platform PE-backed Med-Metrix, supported by Harvest Partners (~$20 billion AUM) and A&M Capital Partners, signed a definitive agreement to acquire Vitalware from Health Catalyst (NASD: HCAT) for $147 million in cash. Vitalware is a Best-in-KLAS mid-revenue cycle software business generating approximately $37 million in FY2025 revenue; its cloud-based chargemaster management, revenue integrity, and coding optimization tools strategically expand Med-Metrix’s platform. For Health Catalyst, the divestiture proceeds retire its ~$160 million senior secured term loan, sharpening the company’s strategic focus. Vitalware was founded in 2011 and acquired by Health Catalyst in 2020. (Link)
  7. New Haven, CT-based Rallybio Corporation (NASD: RLYB) and San Diego-based Avenzo Therapeutics announced a definitive merger agreement — combined company to operate as Avenzo Therapeutics advancing next-generation oncology small molecules and ADCs Rallybio Corporation (NASD: RLYB) and Avenzo Therapeutics announced on June 1, 2026 a definitive merger under which Rallybio acquires Avenzo, with the combined company operating as Avenzo Therapeutics. A concurrent oversubscribed $215 million private placement from healthcare institutional investors and mutual funds funds operations into late 2028 and supports advancement through multiple clinical milestones across next-generation oncology small molecules and ADCs. Pre-transaction Rallybio stockholders will own approximately 2.8% of the combined company; Rallybio intends to distribute substantially all pre-closing net cash to existing stockholders. Closing expected Q4 2026, subject to stockholder approval. (Link)
  8. Murfreesboro, Tennessee-based National HealthCare Corporation (NYSE American: NHC) completed the $50.5 million acquisition of five skilled nursing facilities, converting decades-long management agreements into full ownership across 566 operating beds National HealthCare Corporation (NYSE American: NHC) announced on June 4, 2026 the closing of the $50.5 million purchase of five skilled nursing facilities — four in Tennessee and one in South Carolina, totaling 566 operating beds — from National Health Corporation (an ESOP entity). NHC subsidiaries have managed these facilities since 1988; the acquisition gives NHC full ownership of both operations and real estate. CEO Steve Flatt noted the transition is invisible to patients and partners and will be immediately accretive to cash flow and earnings. (Link)
  9. Westlake Village, California-based LTC Properties (NYSE: LTC) announced a $54 million SHOP acquisition of a 104-unit assisted living and memory care community in Phoenix, Arizona — welcoming MorningStar Senior Living as its eleventh SHOP operator and ninth new partner since the platform’s May 2025 launch LTC Properties, Inc. (NYSE: LTC) announced on June 2, 2026 a $54 million SHOP acquisition of a 104-unit assisted living and memory care community in Phoenix, Arizona, at a 6.75% cap rate with an expected unlevered IRR in the low-to-mid teens. The community will continue to be managed by MorningStar Senior Living — new to LTC and its eleventh SHOP operating partner. Since its SHOP launch, LTC has completed $524 million in SHOP acquisitions, including $171 million in 2026, with SHOP now representing approximately 28% of annualized NOI and 32% of gross investments. LTC targets an additional $285 million in SHOP acquisitions closing by end of Q3 2026. (Link)
  10. New York-based Strata Critical Medical (NASD: SRTA) completed the all-cash acquisition of Louisville Perfusion Services, Inc., a regional perfusion and blood management provider serving cardiac surgery programs in Kentucky, for up to $20 million — adding a Midwest and Southern stronghold to its 275+ hospital national perfusion platform Strata Critical Medical (NASD: SRTA) announced on June 2, 2026 the completed acquisition of Louisville Perfusion Services, Inc. (LPS), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. The transaction consists of approximately $16 million upfront plus up to $4 million in performance-based consideration. LPS is expected to generate approximately $10 million in revenue and $3 million in Adjusted EBITDA for 2026. The deal expands Strata’s cardiac perfusion platform into the Midwest and Southern U.S., adds ECMO support and organ transplant capabilities, and is consistent with Strata’s strategy of bolt-on acquisitions at mid-single digit Adjusted EBITDA multiples. (Link)
  11. Frisco, Texas-based Soleo Health (PE: Court Square Capital Partners and WindRose Health Investors) acquired Realo Specialty Care Pharmacy and BluHaven Management from Realo Drugs, adding a specialty pharmacy and ambulatory infusion center in North Carolina and bringing its national portfolio to 28 specialty pharmacies and 30+ infusion suites Soleo Health, a portfolio company of Court Square Capital Partners and WindRose Health Investors, acquired both Realo Specialty Care Pharmacy and BluHaven Management from Realo Drugs. The dual acquisition adds a specialty pharmacy in Morrisville, N.C., and an ambulatory infusion center in Raleigh, N.C., deepening Soleo’s presence in North Carolina, South Carolina, Virginia, and Maryland. The deal brings Soleo’s national portfolio to 28 specialty pharmacies and over 30 ambulatory infusion suites. (Link)
  12. Salt Lake City-based Bristol Hospice acquired Hope Hospice and Palliative Care, expanding its presence into the greater Memphis, Tennessee market Bristol Hospice, one of the largest hospice providers in the United States, announced on June 1, 2026 the acquisition of Hope Hospice and Palliative Care, bringing compassionate end-of-life services into the greater Memphis community. The acquisition honors Hope Hospice’s legacy of patient-centered care while integrating it into Bristol’s national network and clinical infrastructure. Bristol operates dozens of locations nationwide. (Link)
  13. Southlake, Texas-based Alliance Clinical Network (PE: Amulet Capital Partners and BPOC) completed a strategic merger with Atlas Clinical Research, creating an expanded national clinical trial site network across seven states with nearly 50 years of combined clinical research experience Alliance Clinical Network and Atlas Clinical Research announced on June 2, 2026 the closing of their strategic merger, combining nearly 50 years of collective clinical research experience across sites in Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas. The combined organization serves sponsors across CNS disorders, internal medicine, women’s health, metabolic diseases, dermatology, gastroenterology, pain management, and vaccines. Alliance is backed by Amulet Capital Partners and BPOC; Anthony Milonas serves as CEO. The merger was originally announced May 13, 2026. (Link)
  14. Marietta, Georgia-based Wellstar Health System finalized an agreement to acquire Mountain Lakes Medical Center, a 25-bed critical access hospital and Level IV Trauma Center in Clayton, Georgia, expanding its hospital portfolio from 11 to 12 facilities Wellstar Health System announced a definitive agreement to acquire Mountain Lakes Medical Center (MLMC), a 25-bed critical access hospital and Level IV Trauma Center in Clayton, Ga., serving Rabun County and surrounding northeast Georgia and western North Carolina. The acquisition is expected to close August 1 pending regulatory approvals. Wellstar’s strategic rationale centers on connecting MLMC patients to expanded specialty resources, digital health capabilities, and advanced clinical programs across its growing Georgia footprint. (Link)
  15. New York-based National Healthcare Properties (NASD: NHP), a senior housing REIT, announced approximately $279 million in signed purchase agreements and letters of intent for SHOP acquisitions expected to add 1,214 units to its existing 3,615-unit portfolio National Healthcare Properties (NASD: NHP) announced on June 1, 2026 signed purchase and sale agreements or non-binding letters of intent for approximately $279 million of SHOP acquisitions, with estimated weighted average year-one and year-three cap rates of 8.0% and 9.7%, respectively. The pipeline is expected to add 1,214 units to NHP’s existing 3,615 needs-based senior housing units. NHP also announced its Class A common stock will be added to the Russell 2000 and 3000 Indexes effective after market close on June 26, 2026, following its April 2026 NASD listing. (Link)
  16. Irvine, California-based Discovery Behavioral Health announced an agreement with lender HPS Investment Partners to transfer majority ownership in exchange for a substantial reduction of its $280 million debt obligations, following a December 2025 lender seizure of the company; regulatory approval pending Discovery Behavioral Health — one of the largest behavioral health platforms in the country, formerly backed by Webster Equity Partners — announced on June 2, 2026 an agreement with HPS Investment Partners to transfer majority ownership in exchange for a substantial reduction of its $280 million debt burden. HPS and Capital One originally seized Discovery’s assets in December 2025 after repeated covenant defaults on debt agreements originally entered in June 2021. Discovery briefly contested the takeover in New York state court before abandoning the effort. The announcement formalizes the ownership transfer structure pending regulatory approvals; a CEO change was also announced simultaneously. (Link)
  17. Radnor, Pennsylvania-based Hidden River Strategic Capital invested debt and convertible preferred equity into Redding, California-based Northstar Senior Living to support its merger with North Palm Beach, Florida-based Alta Senior Living, creating a scaled national senior living management platform Hidden River Strategic Capital announced on June 2, 2026 an investment in Northstar Senior Living in connection with its merger with Alta Senior Living. The combined company will operate as Northstar Senior Living, managing assisted living, memory care, and independent living communities under long-term contracts with community owners across the U.S. Hidden River’s investment consisted of debt and convertible preferred equity. Northstar’s executive team will run day-to-day operations; Alta CEO Doug Brawn will serve as Board Chair. Blueprint CRE facilitated the capital partner search and merger. (Link)
  18. San Francisco-based Clarify Health completed the acquisition of Loyal Health Holdings to create healthcare’s first closed-loop network intelligence and patient activation platform, combining referral analytics with AI-powered patient engagement tools across nearly 500 hospitals Clarify Health completed the acquisition of Loyal Health Holdings, Inc., a healthcare-specific patient activation platform, creating what the combined company describes as the industry’s first closed-loop network intelligence engine spanning referral intelligence, patient activation, and outcomes measurement. Loyal’s Care Activation Platform manages over 80,000 provider and location profiles and serves nearly 500 hospitals nationwide. The merged entity pairs Clarify’s Meridian® machine learning platform with Loyal’s AI-powered scheduling, chat, and predictive propensity engines. Clarify CEO Todd Gottula leads the combined company. (Link)
  19. San Juan Capistrano-based The Ensign Group (NASD: ENSG) acquired the real estate and operations of Woodland Health and Rehabilitation, a 62-bed skilled nursing facility in Mount Pleasant, Iowa The Ensign Group (NASD: ENSG) acquired the real estate and operations of Woodland Health and Rehabilitation, a 62-bed skilled nursing facility in Mount Pleasant, Iowa, effective June 1, 2026, through a Standard Bearer Healthcare REIT, Inc. subsidiary. The facility will be operated by an Ensign-affiliated tenant. The acquisition brings Ensign’s total portfolio to 396 healthcare operations across 17 states. (Link)
  20. The Ensign Group (NASD: ENSG) acquired the real estate of Memory Care of Contra Costa, a 46-unit memory care facility in Pleasant Hill, California, effective June 1, 2026, through its Standard Bearer Healthcare REIT subsidiary — to be leased to a third-party operator under a long-term triple net lease Through a subsidiary of Standard Bearer Healthcare REIT, The Ensign Group (NASD: ENSG) acquired the real estate of Memory Care of Contra Costa, a 46-unit memory care facility in Pleasant Hill, California, effective June 1, 2026. The facility will be operated by an experienced third-party operator under a long-term triple net lease. CEO Barry Port called the acquisition a ‘home run’ for the Standard Bearer portfolio. Ensign’s real estate subsidiaries now own 181 real estate assets across its national portfolio. (Link)
  21. Poway, California-based Diazyme Laboratories, Inc. (a General Atomics subsidiary) acquired Carolina Liquid Chemistries Corporation, a Greensboro, North Carolina-based FDA-registered manufacturer and value-added reseller of chemistry systems and reagents Diazyme Laboratories, Inc. announced on June 1, 2026 the acquisition of Carolina Liquid Chemistries Corporation (CLC), an FDA-registered manufacturer and value-added reseller of chemistry systems and reagents founded in 1994 in Greensboro, North Carolina. CLC’s cost-effective reagent products will complement Diazyme’s proprietary enzyme and immunoassay technologies, creating synergies for clinical and reference laboratories of all sizes. CLC’s business will be fully integrated into Diazyme’s operations. Diazyme is a cGMP and ISO 13485 certified medical device manufacturer. (Link)
  22. Bridgepoint has acquired Obagi Medical from Waldencast (NASD: WALD) in a transaction valued at up to $460 million, securing a dermatology and aesthetics skincare business European PE firm Bridgepoint has agreed to acquire Obagi Medical from publicly traded beauty holding company Waldencast (NASD: WALD) in a deal worth up to $460 million. Waldencast originally acquired Obagi Medical in 2022 before expanding it into injectable aesthetics through a bolt-on acquisition. The divestiture allows Waldencast to deleverage its balance sheet and redirect investment exclusively toward Milk Makeup. Bridgepoint’s acquisition provides Obagi Medical with focused, dedicated ownership to advance its position in the rapidly growing physician-dispensed dermatology and aesthetics market, which had expanded to include the FDA-approved Obagi Saypha® MagIQ™ dermal filler range prior to the transaction. (Link)
  23. Geneva, Switzerland-based SGS (SIX: SGSN), the world’s leading testing, inspection and certification company, acquired CMIC, INC., a Chicago, Illinois-based specialized bioanalytical testing services provider — its second U.S. bioanalytical acquisition in two months SGS announced on June 3, 2026 the acquisition of CMIC, INC., a Chicago, Illinois-based provider of bioanalytical testing services established in 2010. CMIC’s 27,000-square-foot GLP-compliant facility delivers bioanalysis across pre-clinical and clinical phases for pharmaceutical and biotech manufacturers developing biologics and complex therapies. CMIC, INC. is a group company of CMIC HOLDINGS Co., Ltd., which will continue collaborating with SGS through its pharmaceutical arm. The deal advances SGS’s Strategy 27 objective to double North American sales between 2023 and 2027. SGS operates over 2,500 laboratories across 115 countries.  (Link)
  24. Guildford, UK-based Venture Life Group (AIM: VLG) agreed to acquire two U.S. women’s health consumer brands — FemiClear and CUROXEN — from Austin, Texas-based OrganiCare Nature’s Sciences for up to $28 million, expanding its intimate health portfolio into Walmart, Walgreens, CVS, and Target Venture Life Group plc (AIM: VLG) announced on June 4, 2026 an agreement to acquire the FemiClear and CUROXEN consumer healthcare brands from OrganiCare Nature’s Sciences for up to $28 million — $23 million upfront and up to $5 million in deferred consideration tied to 2026 trading performance, funded from existing cash. FemiClear addresses gynaecological conditions including bacterial vaginosis, genital herpes, thrush, and UTIs (~98% of combined revenues); CUROXEN provides infection prevention for wounds and mouth sores. Combined net revenues were $12.1 million in the 12 months to March 31, 2026, up 29.1% year-on-year. Distribution spans Walmart, Walgreens, CVS, and Target. Venture Life shares rose approximately 9–10% on announcement. (Link)
  25. Suresnes, France-based Servier agreed to acquire the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (NASD: EWTX) for up to $2.65 billion — $1.55 billion upfront plus up to $1.1 billion in milestones — to advance sevasemten, a first-in-class oral fast skeletal myosin inhibitor for Duchenne and Becker muscular dystrophy French pharmaceutical firm Servier announced on June 1, 2026 a definitive agreement to acquire Edgewise Therapeutics’ (NASD: EWTX) muscular dystrophy business for up to $2.65 billion — $1.55 billion upfront plus up to $1.1 billion in regulatory and commercial milestones. The deal secures sevasemten, a first-in-class oral fast skeletal myosin inhibitor in pivotal testing for Becker muscular dystrophy and mid-stage studies for Duchenne. Edgewise retains its cardiovascular pipeline (EDG-7500 for HCM, EDG-15400 for HFpEF) and becomes a cardiovascular-focused company post-close. All Edgewise employees supporting the muscular dystrophy business will receive comparable offers from Servier. Closing is expected in Q3 2026. (Link)

Venture Deals and Other

  1. Charlottesville, Virginia-based Contraline, Inc. closed a $92.5 million Series B co-led by BVF Partners and RA Capital Management — with GV (Google Ventures), Lumira Ventures, and Invus participating — to advance NES/T Gel, a first-in-class daily hormonal male contraceptive, into late-stage development Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced on June 2, 2026 the closing of a $92.5 million Series B co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Proceeds support late-stage development of NES/T Gel — an investigational, daily, topical, hormonal, reversible male contraceptive with first-in-class potential — and advancement of ADAM, a non-hormonal hydrogel implant in clinical trials. BVF’s Iris van Alderwerelt van Rosenburgh joined the Board. No male contraceptive pill or equivalent has been approved in the U.S.; NES/T Gel addresses a massive unmet need in men’s reproductive health. (Link)
  2. Founders Fund has led a $435 million Series C in NewLimit alongside Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others to fund the first human clinical trial of an aging reprogramming medicine. Founders Fund led NewLimit’s $435 million Series C, joined by new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning backers including Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital. Founded in 2021 by Coinbase (NASD: COIN) CEO Brian Armstrong alongside Blake Byers and CEO Jacob Kimmel, NewLimit is developing epigenetic reprogramming medicines to reverse cellular aging. The raise will fund the company’s lead liver reprogramming therapy into human clinical trials — a timeline dramatically accelerated by a recent prototype breakthrough that demonstrated age reversal in old human liver cells. The company’s long-term vision is to treat aging itself as a clinically addressable condition. (Link)
  3. Felicis, Bain Capital Ventures, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, Dorm Room Fund, and Constellation have co-invested in a $50 million Series A for Adaptive Innovations, an AI-native home health provider based in New York and Dallas. Felicis led a $50 million Series A in Adaptive Innovations, the first AI-native homecare provider, with significant participation from Bain Capital Ventures, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, Dorm Room Fund, and Constellation, along with prominent angels from healthcare and frontier AI. The round brings Adaptive’s total funding to $60 million, including a previously undisclosed $10 million Seed. Since its 2025 launch, Adaptive has achieved an industry-leading sub-5% rehospitalization rate versus an 11% industry average, reduced clinician documentation time by 80%, and delivered over 100,000 visits across partnerships with more than 500 healthcare organizations including every major Texas hospital system. Proceeds will fund platform scaling and clinical workforce expansion into new states. (Link)
  4. General Catalyst and Chemistry led a $35 million Series A in Yuzu Health — with Anthropic’s Anthology Fund, Bain Future Back Ventures, Lachy Groom, and Neo — to modernize health insurance TPA infrastructure with AI-automated claims processing Yuzu Health secured $35 million in Series A funding led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund, Bain Future Back Ventures, Timeless Ventures, Lachy Groom, and Neo. Founded in 2022, Yuzu Health is a vertically integrated third-party administrator (TPA) powering claims processing, payments, and member administration for health plans, with a unified data architecture offered as a white-labeled solution. The company automates historically manual workflows including claims adjudication, stop-loss submissions, reconciliation, and downstream reporting, enabling more customizable plan designs including direct contracts and dynamic copays. (Link)
  5. San Francisco-based Lassie raised $35 million in Series A led by Andreessen Horowitz (a16z) — with Night Capital and fintech founders from Superhuman, Plaid, and Wise — to build AI autonomous systems for small healthcare businesses Lassie raised $35 million in Series A led by Andreessen Horowitz (a16z), with Night Capital and prominent fintech founders from Superhuman, Plaid, and Wise participating. a16z’s Alex Rampell joined the board. Lassie’s platform currently operates in more than 700 dental and doctor practices across 49 states, automating front-office, scheduling, billing, and operational workflows so small healthcare practices can run themselves with reduced administrative overhead. (Link)
  6. New York-based Novellia raised $18 million in Series A led by Spark Capital — with Khosla Ventures, Acrew Capital, Bling Capital, and TMV — to scale its patient-controlled real-world data platform providing anonymized health records for drug R&D Novellia, the only real-world data company built entirely on patient-contributed information, announced an $18 million Series A led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing total funding to $28 million. Alongside the raise, Novellia launched its patient-facing mobile app allowing individuals to securely access and contribute their complete health history. Novellia provides structured real-world datasets to top-10 pharma companies for drug development — addressing what the company calls a $50 billion gap in research-grade patient data. Announced June 2, 2026. (Link)
  7. San Diego-based Rejuvenate Bio (a George Church / Harvard Wyss Institute spinout) announced $6 million in financing and a strategic R&D collaboration with Merck Animal Health to advance gene therapies targeting age-related chronic diseases in animals and humans Rejuvenate Bio, a gene therapy company co-founded by Harvard professor George Church as a spinout from the Harvard Wyss Institute, announced on June 8, 2026 a $6 million financing round and a strategic R&D collaboration with Merck Animal Health. Rejuvenate Bio develops gene therapies targeting the root causes of age-related diseases — including heart failure, kidney failure, Type 2 diabetes, and obesity — in both humans and dogs, using its dual-species strategy to build clinical evidence through companion animal studies while advancing toward human therapeutics. Rejuvenate Bio has previously raised over $10 million in its Series A. (Link)
  8. Houston, Texas-based Goldenrod Therapeutics, Inc. completed the initial closing of a $6.5 million Series Seed round led by Ataxia Ventures and Fannin Partners to advance 11h — a brain-penetrant PDE4 inhibitor — into Phase I clinical trials for Friedreich’s Ataxia and other neurodegenerative diseases Goldenrod Therapeutics, Inc., a Fannin Innovation-founded precision therapeutics company, announced the initial closing of a $6.5 million Series Seed round led by Ataxia Ventures and an affiliate of Fannin Partners. Proceeds fund manufacturing, formulation optimization, IND-enabling studies, and a Phase I trial in Friedreich’s Ataxia (FA) — a rare and progressive neurodegenerative disease — with pharmacodynamic biomarkers of PDE4 pathway modulation. Goldenrod’s lead candidate, 11h, is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor designed at the University of Nebraska Medical Center (UNMC) to overcome emesis limitations of earlier inhibitors. Development has been supported by NIH and Department of Defense grants. (Link)
  9. Aurora Forge, Jackson Healthcare, Peg’s Foundation, and family offices co-invested a $3 million Seed round in Columbus, Ohio-based Radley Health — alongside existing investor CareSource — to fund expansion of its peer-driven mental health platform into Georgia Aurora Forge, Jackson Healthcare, Peg’s Foundation, and prominent family offices participated in a $3 million Seed round for Radley Health, joining existing investor CareSource, a nonprofit health plan headquartered in Dayton, Ohio. Radley Health has built one of the largest peer support networks in Ohio, with over 450 certified peer support specialists in more than 70 counties across a state where 75 of 88 counties face Mental Health Professional Shortage Area designations. Proceeds support peer workforce growth, healthcare provider partnerships, technology enhancements, and a Georgia market launch where the company has already recruited 50 peer support specialists through partnership with the Georgia Mental Health Consumer Network. (Link)
  10. Enable Ventures, Florida Opportunity Fund, Castellan Group, DeepWork Capital, Sawmill Angels, and Black Opal have jointly invested $5.75 million in Kalogon, a Melbourne, Florida-based smart seating solutions company. Enable Ventures — the first venture fund dedicated to closing the disability wealth gap — led a $5.75 million funding round in Melbourne, Fla.-based Kalogon, a smart seating technology company specializing in seated health solutions for wheelchair users, commercial aviation, and other extended-sitting use cases. Participating investors include Florida Opportunity Fund, Castellan Group, and returning backers DeepWork Capital, Sawmill Angels, and Black Opal. The investment follows a strong year for Kalogon, during which the company more than tripled its medical revenue year-over-year and moved into a dedicated manufacturing facility. Kalogon’s technology is currently being tested to reduce fatigue for U.S. Air Force B-52 and E-4B aircrew on extended missions. Proceeds will fund engineering, R&D, and international expansion. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 1st, 2026

LECO_Weekly-Healthcare-News_6-1-2026Download
  1. Healthcare Capital Markets & Innovation Summit (HCMIS 2026) — Day 1 Recap | Theme: “Longevity in Healthcare & Capital Investment” Day 1 of HCMIS 2026 brought together healthcare operators, investors, lenders, innovators, entrepreneurs, and advisors in Columbus, Ohio. The day opened with insights on healthcare deal activity, capital flows, and the state of healthcare credit markets, with a consistent theme: regardless of market conditions, healthcare organizations must continue to innovate, invest, and execute to create long-term value. A fireside discussion with Daryl Tol, President & CEO of HATCo, explored the transformation of health systems and the growing importance of strategic partnerships, innovation platforms, and new operating models. Key discussion tracks included Healthcare Lending & Private Credit, AI & Value-Based Care, Behavioral Health & Health System Innovation, and Healthcare Consumerization. One featured highlight was the “Longevity: Scaling for Healthspan and Lifespan” panel covering preventive care, diagnostics, AI, GLP-1 therapies, and personalized medicine, followed by a lunchtime panel on Longevity as an emerging investment opportunity. The afternoon featured discussions on healthcare M&A, AI in Transactions, Rural Health Innovation, and Strategic Partnerships. New for 2026 was the inaugural Pitch Competition, featuring 13 finalists screened using HDIG’s AI-powered innovation assessment tools, competing for cash prizes, professional services, investment opportunities, and the Blue Jacket Award. (Link)
  2. Eli Lilly (NYSE: LLY) agreed to acquire Seattle-area clinical-stage biotech Curevo Vaccine for up to $1.5 billion in cash — an upfront payment plus a milestone payment — to advance Phase 3-ready next-generation shingles vaccine candidate amezosvatein; Lilly simultaneously announced two additional vaccine acquisitions the same week, bringing total combined consideration to up to ~$3.83 billion Eli Lilly announced on May 26, 2026 agreements to acquire three private vaccine companies simultaneously: Curevo, Inc. (up to $1.5B), LimmaTech Biologics AG (up to $780M), and Vaccine Company, Inc. ($1.55B). Curevo’s lead program, amezosvatein, is a Phase 3-ready adjuvanted subunit shingles vaccine designed to match GSK’s Shingrix on efficacy while reducing side effects by 50%+ in head-to-head Phase 2 data. LimmaTech Biologics is developing vaccines against antimicrobial-resistant bacterial pathogens including S. aureus (LTB-SA7, Phase 1), gonorrhea, and chlamydia. Vaccine Company develops nanoparticle-based vaccines targeting viral diseases. The triple deal signals Lilly’s strategic push into infectious disease prevention using GLP-1 profits, noting common infections are increasingly linked to downstream neurological disease, cancer, and infertility. (Link)
  3. Pfizer (NYSE: PFE) and Suzhou, China-based Innovent Biologics (HK: 01801) entered a global strategic licensing and collaboration agreement for 12 early-stage oncology programs — antibody-drug conjugates and multispecific antibodies — valued at up to $10.5 billion, with $650 million upfront Pfizer and Innovent Biologics announced on May 28, 2026 a strategic global licensing and collaboration agreement covering 12 early-stage cancer medicine programs for up to $10.5 billion. Innovent receives $650 million upfront plus up to $9.85 billion in milestones and double-digit royalties on approved products. The portfolio spans ADCs with novel differentiated payloads and multispecific antibodies with unique immune-engaging designs — eight programs from Innovent, four proposed by Pfizer. The deal is structured in three buckets with varying exclusivity and cost-sharing; Innovent leads Phase 1 trials before Pfizer takes over global development. Innovent shares rose 10%+ in Hong Kong on announcement. One of the largest oncology licensing transactions of 2026, highlighting surging U.S. pharma appetite for Chinese biotech innovation despite geopolitical pressures. (Link)
  4. HCA Healthcare (NYSE: HCA) agreed to acquire The College of Health Care Professions (CHCP), a Texas-based allied health educator with 8,000+ students annually across 10 campuses, to vertically integrate its clinical workforce pipeline HCA Healthcare announced on May 27, 2026 a definitive agreement to acquire The College of Health Care Professions (CHCP), one of the largest allied healthcare training institutions in Texas. CHCP educates more than 8,000 students annually across 10 Texas campuses and online in medical assisting, surgical technology, medical imaging, and allied health programs, and provides continuing education nationwide through its Medical Technology Management Institute. The deal directly addresses the national clinical labor shortage pressuring hospital margins industry-wide. HCA and CHCP have partnered for over a decade through clinical rotations and career placement. Chancellor and CEO Eric Bing will remain to lead CHCP. (Link)
  5. Tractor Supply Company (NASD: TSCO) acquired VIP Petcare veterinary services — the largest provider of mobile veterinary care in the U.S., operating clinics in ~2,700 retail locations across 39 states — from Bansk Group’s PetIQ, bringing vet services in-house across its rural lifestyle retail footprint Tractor Supply Company (NASD: TSCO), the largest rural lifestyle retailer in the U.S., announced on May 28, 2026 it has acquired the veterinary services business VIP Petcare (operating as VIP Petcare and PetVet) from PetIQ, a Bansk Group company. VIP Petcare is the largest provider of mobile veterinary care in the United States, operating community clinics in approximately 2,700 retail locations — including 1,700 locations — across 39 states and serving more than one million pets annually. Bringing VIP Petcare in-house deepens Tractor Supply’s omnichannel pet health platform alongside its Petsense by Tractor Supply stores and Allivet digital pharmacy. (Link)
  6. Mesquite, Texas-based Ernest Health signed a definitive agreement to acquire Reunion Rehabilitation Hospitals — a seven-hospital network across Arizona, Colorado, Texas, and Florida — expanding its footprint from 38 to 45 rehab hospitals Ernest Health, a national post-acute rehabilitation operator, signed a definitive agreement to acquire Reunion Rehabilitation Hospitals, a network of seven medical rehabilitation hospitals in Arizona, Colorado, Texas, and Florida. The deal lifts Ernest’s network from 38 to 45 rehabilitation hospitals nationwide. President and CEO Jake Socha said Reunion’s mission and culture align with Ernest’s locally led hospital model, and the transition will proceed over coming months with no disruption to operations; Reunion employees can remain and join Ernest. (Link)
  7. AI-driven healthcare-engagement platform Swoop acquired prescription-management platform Nimble (NimbleRx) — which serves 16 million patients across independent pharmacies in all 50 states — to add prescription fulfillment and pharmacy connectivity Swoop, an AI-driven, privacy-compliant healthcare marketing platform for life sciences, acquired Nimble (also known as NimbleRx), a prescription-management platform spanning independent pharmacies in all 50 states and enabling 16 million patients to fill, refill, pay for, and manage prescriptions. The combined offering, branded SwoopRx by Nimble, adds prescription fulfillment, pharmacy connectivity, and adherence tools to Swoop’s portfolio. CEO Ron Elwell said the deal extends Swoop “beyond engagement to impact,” while Nimble founder/CEO Talha Sattar emphasized closing the gap between prescription and adherence. Financial terms were not disclosed. The acquisition follows Swoop’s earlier purchase of MyHealthTeam. (Link)
  8. Chicago-based private credit manager Monroe Capital acted as lead arranger and administrative agent on a senior credit facility backing private equity sponsor Warburg Pincus’ investment in Waco, Texas-based home-based care provider Cornerstone Caregiving (terms undisclosed). Monroe Capital LLC arranged and administered a senior credit facility to support private equity firm Warburg Pincus’ investment in Cornerstone Caregiving, a Waco, Texas home-based care provider founded in 2020 that offers hospice, home care, palliative care, and senior services (including Alzheimer’s and dementia care) across hundreds of U.S. locations; financial terms were not disclosed. Monroe framed the deal as continued PE appetite for non-acute, lower-cost care delivery as hospitals and insurers shift volume out of institutional settings. Warburg Pincus, founded in 1971, has invested over $130 billion across 1,100-plus companies; the financing adds to Chicago-based Monroe’s growing healthcare-services private credit portfolio. (Link)
  9. Cleveland, Ohio- and Dallas-based private equity firm Align Capital Partners (ACP) acquired Heritage Imaging, a mobile diagnostic imaging provider serving hospitals across 14 states, as a new platform investment Align Capital Partners (ACP), a lower-middle-market PE firm headquartered in Cleveland, Ohio (Shaker Heights) and Dallas with $2.1 billion in committed capital, acquired Heritage Imaging as its next platform. Founded in 1989, Heritage provides fully staffed mobile diagnostic imaging — PET/CT, MRI, nuclear medicine, ultrasound and echocardiography — to hospitals across 14 states, focusing on rural and underserved markets. CEO Dr. Steve Coppess and the management team stay on. ACP’s Rob Langley led the deal and plans further M&A in outsourced imaging; Heritage has closed three add-ons since 2024. (Link)
  10. Baltimore, Maryland-based Procare Ambulance entered a strategic partnership with Prodos Capital and Manolin Investment Group — with growth capital from Tecum Capital, Genesis Park Capital, and SharpVue Capital — to expand its Mid-Atlantic emergency and non-emergency interfacility transport and Mobile Integrated Health platform Procare Ambulance of Maryland, a Baltimore-based provider of non-emergency and emergency interfacility transportation (IFT) services serving the Maryland and Washington, D.C. markets with recent expansion into Virginia, entered a strategic partnership with Prodos Capital and Manolin Investment Group on June 1, 2026. Tecum Capital, Genesis Park Capital, and SharpVue Capital provided growth capital to support the partnership. Procare delivers Basic Life Support, Advanced Life Support, Specialty and Critical Care Transport, Mobile Integrated Health (MIH), and medical standby services to a roster of healthcare institutions across the Mid-Atlantic. Founder Debbie Ailiff and CEO Mark Bucholtz will remain to lead the business; the partnership will support geographic expansion into Virginia, development of the MIH program, and investment in workforce and fleet. (Link)
  11. New Hyde Park, NY-based Premier Care Dental Management (PCDM) acquired Brett Pelok, DDS & Associates, a general dental practice in Toledo, Ohio led by Ohio Dental Association President-Elect Dr. Brett Pelok, deepening PCDM’s Ohio presence Premier Care Dental Management (PCDM), a multi-state Dental Clinical Organization, acquired Brett Pelok, DDS & Associates, a general dental practice in Toledo, Ohio. The practice is owned by Dr. Brett Pelok, President-Elect of the Ohio Dental Association, who will continue leading clinical care post-transaction. CEO and founder Dr. Scott Asnis said the deal supports PCDM’s growth while letting the practice keep its identity and clinical leadership. PCDM operates across NY, CT, NJ, PA, OH, NH, MA, and RI. (Link)
  12. Chicago-based, doctor-owned PE platform Phase 1 Equity added a multi-site orthodontic practice in Texas — its third practice acquisition of 2026 — bringing the network to 21 doctors and 31 locations Phase 1 Equity, a Chicago-based doctor-owned, doctor-led PE platform for orthodontists and pediatric dentists, added another multi-site orthodontic practice in Texas. This marks its third practice addition of 2026, its third in Texas, its 21st affiliated doctor, and lifts total locations to 31. CEO Mike Rice cited continued momentum as more doctors recognize the platform’s value. Doctors retain clinical control while gaining shared services and PE-style resources. (Link)
  13. MorningStar Senior Living recapitalized its 112-unit Houston assisted-living and memory-care community, River Oaks, with TPG Angelo Gordon U.S. Real Estate, retaining long-term management of the Class-A property MorningStar Senior Living recapitalized MorningStar at River Oaks, a Class-A, 112-unit assisted-living and memory-care community in Houston, with investor TPG Angelo Gordon U.S. Real Estate. MorningStar co-developed the community (opened 2021) and will continue managing it under a long-term agreement, deepening its relationship with TPG Angelo Gordon. MorningStar’s portfolio spans 38 communities (operating or in development), 5,000+ units across 11 states. (Link)
  14. Tokyo-based Olympus Corporation agreed to acquire Tel Aviv-area VC-backed MedTech company BioProtect Ltd. for $270 million, adding a prostate cancer radiation spacer device to its urology and oncology portfolio Olympus Corporation announced on May 26, 2026 a definitive agreement to acquire Israel-based BioProtect Ltd. (backed by MVM Partners) for $270 million. BioProtect’s Balloon Spacer is an implantable hydrogel that creates a temporary physical barrier between the prostate and rectum during radiation therapy, reducing healthy-tissue exposure and improving treatment precision in prostate cancer — the second most commonly diagnosed cancer in men globally (~1.5 million new cases/year). The deal extends Olympus’ oncology and urology portfolio adjacent to its core endoscopy platform, consistent with its “Innovation-Driven Growth” strategy. (Link)
  15. Bain Capital agreed to sell Australian residential aged-care provider Estia Health to alternative investment firm Stonepeak, exiting an asset it grew from 73 to 93 homes since 2023 Bain Capital signed an agreement to sell Estia Health, one of Australia’s leading residential aged-care providers, to alternative investment firm Stonepeak; financial terms were not disclosed. Bain Capital acquired Estia in December 2023 and, over its hold, grew the business from 73 homes serving ~6,720 residents to 93 homes serving ~9,250 residents, with more than 14,000 employees. The Bain investment was led by Australia-based partners Mike Murphy, Charles Lawson, and Grace Mollard. The transaction is expected to close in late 2026, subject to regulatory approvals. Bain Capital manages approximately $225 billion in assets across its global platform. (Link)
  16. Dallas, Texas-based PE firm Highlander Partners backed the merger of Bucharest-based MONZA-ARES — Romania’s leading private cardiology and complex surgery hospital group — with Brain Institute, the country’s premier private neurosurgery center, to form one of Romania’s leading private hospital operators MONZA-ARES, Romania’s leading private hospital group focused on cardiology and complex surgery, and Brain Institute, the country’s premier private neurosurgery center, announced on May 26, 2026 they are combining operations to create one of Romania’s leading private healthcare platforms. The merged group is backed by Dallas-based private equity firm Highlander Partners (managing over $3 billion in assets), which has held a majority stake in MONZA-ARES since 2019. The expanded group spans cardiology, neurosurgery, ENT, orthopedics, thoracic surgery, general surgery, and gynecology across facilities in Bucharest, Cluj-Napoca, Constanța, Târgu Jiu, Tulcea, and Onești. Brain Institute shareholders are reinvesting into the combined group. Raiffeisen Bank Romania provided acquisition financing. (Link)
  17. Basel, Switzerland-based CDMO CordenPharma (PE: Astorg) to acquire North Augusta, South Carolina- and Shanghai-based peptide API CDMO AmbioPharm, adding ~400 employees and expanding global peptide manufacturing platform across three continents CordenPharma, the Basel-based global CDMO majority-owned by pan-European PE firm Astorg since 2022, announced on May 27, 2026 an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO with facilities in North Augusta, South Carolina and Shanghai, China. AmbioPharm employs approximately 400 people across its two sites and brings SPPS, LPPS, and hybrid peptide synthesis capabilities that complement CordenPharma’s proprietary Tag-Assisted Peptide Synthesis (TAPS). The North Augusta site becomes CordenPharma’s second U.S. peptide facility, adding purification and lyophilization capacity; the Shanghai campus is CordenPharma’s first Asia-based production footprint. The deal gives pharma customers fully U.S.-based or global supply options for complex, long-chain peptide APIs — strategically timed given rising GLP-1 peptide demand. CordenPharma generated €960 million in sales and employs more than 3,000 across its 11-site network. AmbioPharm shareholders will reinvest into the combined business. (Link)

Venture Deals and Other

  1. Garner Health, a digital care-navigation platform for employers, closed a $100 million Series E at a $2.74 billion valuation led by Index Ventures, with existing backers Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures Garner Health closed a $100 million Series E led by Index Ventures, with existing investors Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures participating, pushing its valuation to $2.74 billion. The round comes just three months after a $118 million Series D. Index partner Jahanvi Sardana praised Garner for making physician quality measurable via AI. The startup, which uses 60 billion-plus medical records to rank providers and steers ~2.5 million members across nearly 800 clients to high performers, will fund its provider-quality platform, AI product development, and member expansion. (Link)
  2. Healthcare data platform H1 secured a $40 million round led by CVS Health Ventures, the corporate venture arm of CVS Health (NYSE: CVS), validating that profitable, data-centric SaaS startups can still attract capital H1, a nine-year-old healthcare data platform that sells detailed physician information to pharma, hospital systems, and insurers, secured $40 million led by CVS Health Ventures, the corporate VC arm of CVS Health (NYSE: CVS). CEO Ariel Katz said H1 wasn’t seeking capital — the company turned cash-flow and EBITDA profitable last year and projects 40%+ growth — but found partnering with a major healthcare player compelling. H1 was last valued at $750 million in a 2021 round led by Altimeter Capital, and acquired Veda and Ribbon Health and grown. (Link)
  3. San Diego-based ClearNote Health closed a $52 million Series D — led by founding investor Mattias Westman — to scale its blood-based early detection tests for pancreatic and ovarian cancer, bringing total funding to $185 million+ ClearNote Health closed a $52 million Series D on May 27, 2026, led by founding investor Mattias Westman with participation from former Citigroup CEO Sandy Weill, Stanford co-founder Dr. Stephen Quake, and institutional investors, bringing total funding to more than $185 million. ClearNote’s Avantect tests use multiomic blood analysis and machine learning to detect pancreatic and ovarian cancers at early stages — two cancers with very limited detection options and poor late-stage survival rates. The company’s multi-cancer detection test was selected for the NCI’s Vanguard Study. Kevin Keegan — formerly GM of Oncology at Illumina and senior leader at BD and Hologic — joined as President and COO alongside the close. (Link)
  4. Oncology-AI startup Triomics raised $22 million in Series B funding led by Battery Ventures, with returning backers Nexus Venture Partners, Lightspeed, and Y Combinator, to bring oncology-specific AI to cancer centers Triomics raised $22 million in a Series B led by Battery Ventures, with returning investors Nexus Venture Partners, Lightspeed, and Y Combinator participating. Founded in 2021, the startup builds oncology-specific AI to automate data-heavy tasks like clinical-trial matching, patient summaries, and tumor-registry reporting; it previously raised a $15 million Series A in mid-2024. Co-founder Sarim Khan said models trained on oncology data win institutions like Memorial Sloan Kettering and Yale Cancer Center over generic scribes such as Abridge and Microsoft’s Nuance. Triomics grew its enterprise base fourfold and recurring revenue tenfold over the past year. (Link)
  5. Silicon Valley metabolic-health startup Signos raised $20 million — with Dexcom (NASDAQ: DXCM), Blue Cross Blue Shield of Alabama, and GV (Google Ventures) participating — to expand its FDA-cleared continuous glucose monitoring platform for weight management Signos raised $20 million to scale its glucose-monitoring platform for weight loss, with Dexcom (NASDAQ: DXCM), Blue Cross Blue Shield of Alabama, and GV (Google Ventures) participating; the round brings total funding to $57 million since 2018. Signos pairs Dexcom’s over-the-counter Stelo sensor with an AI-powered app delivering personalized diet and lifestyle guidance. Investors view it as complementary to GLP-1 drugs, helping users sustain results through behavior change. CEO Sharam Fouladgar-Mercer said the company is targeting self-insured employers as its primary growth channel as it deploys the new capital. (Link)
  6. Plano, Texas-based Secretome Therapeutics closed a $30 million Series A — with RA Capital Management as the sole investor — to advance STM-01, an nCPC-derived therapy for Duchenne muscular dystrophy cardiomyopathy, into pivotal trials Secretome Therapeutics closed a $30 million Series A on May 27, 2026 with RA Capital Management as the sole investor. Proceeds advance STM-01, a therapy derived from neonatal cardiac progenitor cells (nCPCs) targeting Duchenne muscular dystrophy-associated cardiomyopathy — a leading cause of mortality in DMD patients with very few disease-modifying treatment options. The company intends to move STM-01 into pivotal Phase 2 and Phase 3 development. DMD affects approximately 1 in 3,500–5,000 male births globally. RA Capital’s sole-investor structure signals exceptional conviction in the program’s differentiated biology. Former Ra Pharmaceuticals CFO David Lubner joined the Board alongside the close. (Link)
  7. New York-based Solstice, an AI-native pharma commercialization platform, raised $21 million in Series A funding led by Transformation Capital — with Twelve Below and Virtue Ventures participating — to accelerate MLR review compression from months to days Solstice raised $21 million in Series A financing announced May 28, 2026, led by Transformation Capital with Twelve Below, Virtue Ventures, and others, bringing total funding to approximately $25 million. Biopharma companies spend more than $100 billion annually on commercialization, yet medical, legal, and regulatory (MLR) review cycles can stretch three months for routine marketing assets. Solstice compresses that timeline to under 10 days through AI-native content creation, automated regulatory review, fair balance scoring, and performance tracking in a single compliant workflow. The company already serves over a dozen pharma brands including several top-20 global names. (Link)
  8. Boston-based sleep-tech startup SOND exited stealth with $7 million from E14 Fund, Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele to launch its closed-loop Dreambuds sleep earbuds SOND, founded by MIT grads including Bose’s former Head of Global Sleep Yadid Ayzenberg, emerged from stealth with $7 million from E14 Fund (MIT-affiliated), Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele. The funding accompanies its debut product, Dreambuds — closed-loop in-ear devices capturing 12 physiological signals and feeding a cloud-based AI sleep coach. SOND aims for mass production by Q2 2026 following a planned crowdfunding campaign, and is currently taking reservations. (Link)
  9. New York-based Kubera Health raised $6.5 million in seed funding led by Upfront Ventures — with Company Ventures, Dria Ventures, and SemperVirens participating — to build the contract-to-payment infrastructure layer for U.S. healthcare Kubera Health raised $6.5 million in seed funding announced May 28, 2026, led by Upfront Ventures with Company Ventures, Dria Ventures, and SemperVirens participating. Founded by physician-executive Roja Garimella, MD, MBA, Kubera is building the contract-to-payment system of record for American healthcare — translating complex payor-provider contracts and fee schedules into structured, continuously auditable logic running against claims and payment data in real time. The AMA estimates one in five commercial claims is processed inaccurately, contributing to roughly $1 trillion in annual administrative burden. Early enterprise customers including Hollywood Presbyterian Medical Center have expanded their engagements. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities

CLICK HERE